0001171843-24-001239 | 10-K | XBRL Viewer

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	2023			2022
Volatility		56.8	%		62.6	%
Risk-free interest rate		4.6	%		2.1	%
Correlation coefficient		41.7	%		41.5	%
Dividend yield		-	%		-	%
Liquidity discount		14.1	%		11.7	%

Note 13 - Revenues - Warranties (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Balance	$ 268	$ 240
Expense	381	408
Warranty claims	(313)	(380)
Balance	$ 336	$ 268

Note 10 - Derivatives (Details Textual) $ in Thousands	Dec. 31, 2023 USD ($)
The Credit Agreement [Member]
Debt Instrument, Interest Rate, Stated Percentage	4.75%
Interest Rate Swap [Member]
Derivative, Notional Amount	$ 27,375

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Net loss	$ (3,415)	$ (9,516)
Other comprehensive income (loss):
Foreign currency translation adjustments	1,507	(2,614)
Defined benefit pension plans, net of tax benefit of $137 and $566, respectively	(446)	(2,411)
Derivative instruments qualifying as cash flow hedges, net of tax of $-0-	(199)	0
Other comprehensive income (loss)	862	(5,025)
Comprehensive loss	$ (2,553)	$ (14,541)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Amount after tax and reclassification adjustments of other comprehensive income (loss).

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481674/830-30-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-17

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-4

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-20

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482739/220-10-55-15

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Note 5 - Balance Sheet Information

12 Months Ended

Dec. 31, 2023

Supplemental Balance Sheet Disclosures [Text Block]

5.	Balance Sheet Information

The following tables provide details of selected balance sheet items as of the periods indicated:

*Inventories:*	December 31,
(in thousands)	2023		2022
Finished goods	$	5,120	$	5,223
Work in process		4,188		3,776
Raw materials		15,408		17,440
Total	$	24,716	$	26,439

*Property, Plant and Equipment:*	December 31,
(in thousands)	2023			2022
Machinery and equipment	$	8,154		$	7,500
Computer equipment and software		6,493			6,781
Leasehold improvements		2,417			2,507
Furniture and fixtures		1,244			1,386
Automobiles		58			38
		18,366			18,212
Less: accumulated depreciation		(14,385	)		(14,846	)
Property, plant and equipment, net	$	3,981		$	3,366

Depreciation expense was $1.5 million for each of the years ended December 31, 2023 and 2022. During the year ended December 31, 2023, the Company wrote off approximately $2.0 million of fully depreciated property and equipment from its fixed asset records.

*Other Current Liabilities:*	December 31,
(in thousands)	2023		2022
Compensation	$	3,929	$	3,476
Customer credits		3,201		2,368
Professional fees		499		392
Warranty costs		336		268
Other		1,240		982
Total	$	9,205	$	7,486

Long-lived Assets by Geographic Area:

Long-lived assets by geographic area, which include operating lease right-of-use assets, property, plant and equipment, and amortizable intangible assets, are as follows:

	December 31,
(in thousands)	2023		2022
United States	$	21,558	$	26,051
Germany		1,703		2,432
Rest of the world		1,322		1,489
Total long-lived assets	$	24,583	$	29,972

Note 13 - Revenues - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Balance, beginning of period	$ 191	$ 136
Provision for expected credit losses	29	62
Charge-offs and other	(60)	(7)
Balance, end of period	$ 160	$ 191

Note 14 - Income Tax - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Inventory	$ 1,489	$ 1,696
Operating loss and credit carryforwards	11,550	14,883
Research and development	3,908	2,000
Employee retention credit	1,435	0
Lease liabilities	1,317	1,538
Accrued expenses	818	621
Stock compensation	670	675
Deferred interest expense	386	881
Other assets	934	726
Total gross deferred assets	22,507	23,020
Less: valuation allowance	(15,222)	(14,506)
Deferred tax assets	7,285	8,514
Indefinite-lived intangible assets	1,964	1,914
Definite-lived intangible assets	3,733	4,875
Lease right-of-use assets	959	1,148
Employee benefit plans	569	579
Other liabilities	400	255
Total deferred tax liabilities	7,625	8,771
Deferred income tax liabilities, net	(340)	(257)
Deferred tax assets (included in other long-term assets)	436	333
Deferred income tax liabilities	$ (776)	$ (590)

Note 17 - Product Line Disposition (Details Textual) - USD ($) $ in Thousands		12 Months Ended
	Feb. 17, 2023	Dec. 31, 2023	Dec. 31, 2022
Gain (Loss) on Disposition of Business		$ 403	$ (0)
Hoefer Product Line [Member] \| Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Disposal Group, Including Discontinued Operation, Consideration	$ 500
Disposal Group, Including Discontinued Operation, Assets	100
Gain (Loss) on Disposition of Business	$ 400

Note 13 - Revenues - Revenue by Geographic Destination (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total revenues	$ 112,250	$ 113,335
UNITED STATES
Total revenues	48,205	49,912
Europe [Member]
Total revenues	32,801	30,687
Greater China [Member]
Total revenues	18,488	16,393
Rest of the World [Member]
Total revenues	$ 12,756	$ 16,343

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

Note 5 - Balance Sheet Information (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Inventory, Current [Table Text Block]

*Inventories:*	December 31,
(in thousands)	2023		2022
Finished goods	$	5,120	$	5,223
Work in process		4,188		3,776
Raw materials		15,408		17,440
Total	$	24,716	$	26,439

Property, Plant and Equipment [Table Text Block]

*Property, Plant and Equipment:*	December 31,
(in thousands)	2023			2022
Machinery and equipment	$	8,154		$	7,500
Computer equipment and software		6,493			6,781
Leasehold improvements		2,417			2,507
Furniture and fixtures		1,244			1,386
Automobiles		58			38
		18,366			18,212
Less: accumulated depreciation		(14,385	)		(14,846	)
Property, plant and equipment, net	$	3,981		$	3,366

Other Current Liabilities [Table Text Block]

*Other Current Liabilities:*	December 31,
(in thousands)	2023		2022
Compensation	$	3,929	$	3,476
Customer credits		3,201		2,368
Professional fees		499		392
Warranty costs		336		268
Other		1,240		982
Total	$	9,205	$	7,486

Long-Lived Assets by Geographic Areas [Table Text Block]

	December 31,
(in thousands)	2023		2022
United States	$	21,558	$	26,051
Germany		1,703		2,432
Rest of the world		1,322		1,489
Total long-lived assets	$	24,583	$	29,972

Note 14 - Income Tax - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Balance	$ 1,983	$ 1,332
Additions based on tax positions of prior years	13	534
Decreases based on tax positions of prior years	(57)	(34)
Additions based on tax positions of current year	245	237
Other decreases, net	(76)	86
Decreases based on tax positions of prior years	57	34
Balance	$ 2,222	$ 1,983

Note 7 - Employee Benefit Plans - Change in Benefit Obligations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan, Benefit Obligation, Balance	$ 13,263	$ 22,562
Interest cost	665	371
Actuarial loss (gain)	479	(6,912)
Benefits paid	(563)	(592)
Currency translation adjustment	819	(2,166)
Defined Benefit Plan, Benefit Obligation, Balance	14,663	13,263
Defined Benefit Plan, Fair Value of Plan Assets	16,940	15,576	$ 27,252
Benefit obligation	14,663	13,263	$ 22,562
Net funded status	5,909	5,326
Pension Plan [Member]
Defined Benefit Plan, Benefit Obligation, Balance	13,263
Defined Benefit Plan, Benefit Obligation, Balance	14,663	13,263
Defined Benefit Plan, Fair Value of Plan Assets	16,940	15,576
Benefit obligation	14,663	13,263
Net funded status	$ 2,277	$ 2,313

Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.

Note 3 - Accumulated Other Comprehensive Loss - Changes in Each Component of Other Comprehensive Loss, Net of Tax (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Balance	$ 72,220	$ 83,401
Other Comprehensive Income (Loss), Net of Tax	862	(5,025)
Balance	73,074	72,220
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	(11,392)	(8,778)
Other Comprehensive Income (Loss), Net of Tax	1,507	(2,614)
Balance	(9,885)	(11,392)
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Balance	(3,660)	(1,249)
Other Comprehensive Income (Loss), Net of Tax	(446)	(2,411)
Balance	(4,106)	(3,660)
AOCI Attributable to Parent [Member]
Balance	(15,052)	(10,027)
Other Comprehensive Income (Loss), Net of Tax	862	(5,025)
Balance	(14,190)	$ (15,052)
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]
Other Comprehensive Income (Loss), Net of Tax	(199)
Balance	$ (199)

Amount after tax and reclassification adjustments of other comprehensive income (loss).

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

Note 5 - Balance Sheet Information - Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Finished goods	$ 5,120	$ 5,223
Work in process	4,188	3,776
Raw materials	15,408	17,440
Total	$ 24,716	$ 26,439

Note 14 - Income Tax - Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income tax benefit computed at federal statutory tax rate	$ (537)	$ (1,927)
Permanent differences, net, amount	(89)	375
Non-deductible executive compensation	324	346
Global Intangible Low-Taxed Income (GILTI)	537	552
State income taxes, net of federal income tax benefit, amount	(19)	(295)
Stock-based compensation	(329)	69
Tax credits	(51)	492
Net operating loss true-ups and expirations	1,140	431
Change in reserve for uncertain tax position	239	688
Impact of change to prior year tax accruals	(171)	(232)
Change in valuation allowance allocated to income tax	631	(102)
Other	(816)	(60)
Total income tax expense (benefit)	$ 859	$ 337

Note 7 - Employee Benefit Plans (Details Textual) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)
Defined Contribution Plan, Cost	$ 1.1
Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year	0.6
Defined Benefit Plan, Expected Future Benefit Payment, Year One	0.9
Defined Benefit Plan, Expected Future Benefit Payment, Year Two	0.7
Defined Benefit Plan, Expected Future Benefit Payment, Year Three	0.8
Defined Benefit Plan, Expected Future Benefit Payment, Year Four	1.0
Defined Benefit Plan, Expected Future Benefit Payment, Year Five	0.8
Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years	$ 5.0

Note 15 - Commitments and Contingent Liabilities (Details Textual) $ in Thousands	Dec. 31, 2023 USD ($)
Director [Member] \| Indemnification Agreements [Member]
Liability for Contingent Indemnification Obligations	$ 0

Note 10 - Derivatives - Derivative Instruments (Details) - Interest Rate Swap [Member] $ in Thousands	Dec. 31, 2023 USD ($)
Interest rate swap	$ 27,375
Interest rate swap	$ (199)

Note 18 - Government Assistance (Details Textual) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Feb. 29, 2024	Dec. 31, 2023	Dec. 31, 2022
Programs Established to Offset the Impact of COVID [Member]
Government Assistance, Amount		$ 0.2	$ 0.7
Paycheck Protection Program CARES Act [Member] \| Subsequent Event [Member]
Government Assistance, Amount	$ 3.1

Note 10 - Derivatives (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Derivative Instruments [Table Text Block]

(in thousands)		December 31, 2023
Derivatives Instruments	Balance Sheet Classification	Notional Amount		Fair Value (a)
Interest rate swap	Other long-term liabilities	$	27,375	$	(199	)

Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]

	Year Ended
Derivatives Qualifying as Hedges, net of tax (in thousands)	December 31, 2023
Amount of loss recognized in OCI on derivatives (effective portion)	$	199
Amounts reclassified from accumulated other comprehensive loss to interest expense		120

Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.

Note 7 - Employee Benefit Plans - Weighted Average Assumptions (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Discount rate	4.60%	5.00%
Expected return on assets	5.30%	5.00%

Note 7 - Employee Benefit Plans - Change in Fair Value of Plan Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Defined Benefit Plan, Fair Value of Plan Assets, Balance	$ 15,576	$ 27,252
Actual return on plan assets	351	(9,098)
Employer contributions	622	619
Benefits paid	(563)	(592)
Currency translation adjustment	954	(2,605)
Defined Benefit Plan, Fair Value of Plan Assets, Balance	$ 16,940	$ 15,576

Note 5 - Balance Sheet Information - Long-lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Long-Lived Assets	$ 24,583	$ 29,972
UNITED STATES
Long-Lived Assets	21,558	26,051
GERMANY
Long-Lived Assets	1,703	2,432
Rest of the World [Member]
Long-Lived Assets	$ 1,322	$ 1,489

Note 6 - Restructuring and Other Exit Costs

12 Months Ended

Dec. 31, 2023

Restructuring and Related Activities Disclosure [Text Block]

6.	Restructuring and Other Exit Costs

On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify operational efficiencies, enhance commercial capabilities and align its cost base and infrastructure with customer needs and its strategic plans. In order to realize these opportunities, the Company undertakes activities from time to time to transform its business. A portion of these transformation activities are considered restructuring costs under ASC 420, Exit or Disposal Cost Obligations, and are discussed below.

During the year ended December 31, 2022, the Company reviewed its product portfolio and identified certain non-strategic products for discontinuation and incurred severance expenses in connection with headcount reductions in Europe and North America. The following table summarizes the restructuring activity for the years ended December 31, 2023 and 2022:

(in thousands)	Inventory Related			Severance			Other			Total
Balance at December 31, 2021	$	-		$	-		$	-		$	-
Restructuring and other exit costs		1,471			877			46			2,394
Non-cash charges		(1,471	)		-			-			(1,471	)
Cash payments		-			(241	)		(46	)		(287	)
Balance at December 31, 2022		-			636			-			636
Restructuring and other exit costs		320			42			29			391
Non-cash charges		(142	)		-			-			(142	)
Cash payments		(94	)		(678	)		(29	)		(801	)
Balance at December 31, 2023	$	84		$	-		$	-		$	84

Substantially all of the severance and other costs detailed above have been included as a component of general and administrative expenses, and all inventory-related charges are included in cost of revenues.

Note 2 - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Net loss	$ (3,415)	$ (9,516)
Weighted average shares outstanding - basic (in shares)	42,420	41,413
Dilutive effect of equity awards (in shares)	0	0
Weighted average shares outstanding - diluted (in shares)	42,420	41,413
Basic loss per share (in dollars per share)	$ (0.08)	$ (0.23)
Diluted loss per share (in dollars per share)	$ (0.08)	$ (0.23)
Shares excluded from diluted loss per share due to their anti-dilutive effect (in shares)	3,868	3,661

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Note 13 - Revenues

12 Months Ended

Dec. 31, 2023

Revenue from Contract with Customer [Text Block]

13.

Revenues

The following table represents a disaggregation of revenue from contracts with customers for the years ended December 31, 2023 and 2022:

	Year Ended December 31,
(in thousands)	2023		2022
Instruments, equipment, software and accessories	$	105,716	$	108,165
Service, maintenance and warranty contracts		6,534		5,170
Total revenues	$	112,250	$	113,335

Revenues by timing of recognition are as follows:

	Year Ended December 31,
(in thousands)	2023		2022
Goods and services transferred at a point in time	$	108,558	$	111,927
Goods and services transferred over time		3,692		1,408
Total revenues	$	112,250	$	113,335

Revenues by geographic destination are as follows:

	Year Ended December 31,
(in thousands)	2023		2022
United States	$	48,205	$	49,912
Europe		32,801		30,687
Greater China		18,488		16,393
Rest of the world		12,756		16,343
Total revenues	$	112,250	$	113,335

Contract Liabilities

The following tables provide details of contract liabilities as of the periods indicated:

	December 31,							December 31,
(in thousands)	2023		2022		Change			2022		2021		Change
Service contracts	$	2,849	$	1,530	$	1,319			1,530	$	1,976	$	(446	)
Customer advances		1,659		1,840		(181	)		1,840		2,290		(450	)
Total contract liabilities	$	4,508	$	3,370	$	1,138			3,370	$	4,266	$	(896	)

Changes in the Company’s contract liabilities are primarily due to the timing of receipt of payments under service and warranty contracts. During the years ended December 31, 2023 and 2022, the Company recognized revenue of $2.1 million and $2.5 million from contract liabilities existing at December 31, 2022 and 2021, respectively.

Provision for Expected Credit Losses on Receivables

Activity in the provision for expected losses on receivables is as follows:

	December 31,
(in thousands)	2023			2022
Balance, beginning of period	$	191		$	136
Provision for expected credit losses		29			62
Charge-offs and other		(60	)		(7	)
Balance, end of period	$	160		$	191

Concentrations

No customer accounted for more than 10% of the revenues for the years ended December 31, 2023 and 2022, or for more than 10% of net accounts receivable at December 31, 2023 and 2022.

Warranties

Activity in the product warranty accrual is as follows:

	Year Ended December 31,
(in thousands)	2023			2022
Balance at December 31, 2022	$	268		$	240
Expense		381			408
Warranty claims		(313	)		(380	)
Balance at December 31, 2023	$	336		$	268

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net loss	$ (3,415)	$ (9,516)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation	1,473	1,453
Amortization of intangible assets	5,525	6,122
Amortization of deferred financing costs	280	280
Stock-based compensation expense	5,000	4,411
Deferred income taxes and other	336	(414)
Unrealized loss on equity securities - Note 16	632	(0)
Convertible preferred stock received in litigation settlement - Note 16	0	(3,900)
Gain on sale of product line	(403)	0
Changes in operating assets and liabilities:
Accounts receivable	810	4,780
Inventories	1,524	252
Other assets	1,651	474
Accounts payable and other current liabilities	555	(1,399)
Contract liabilities	1,138	(896)
Other liabilities	(1,078)	(495)
Net cash provided by operating activities	14,028	1,152
Cash flows from investing activities:
Additions to property, plant and equipment	(1,788)	(1,590)
Capitalized software development costs	(523)	0
Proceeds from sale of product line	512	0
Net cash used in investing activities	(1,799)	(1,590)
Cash flows from financing activities:
Borrowing from revolving line of credit	4,500	7,800
Repayment of revolving line of credit	(10,950)	(6,400)
Repayment of term debt	(4,091)	(3,186)
Proceeds from exercise of stock options and employee stock purchase plan	930	577
Taxes paid related to net share settlement of equity awards	(2,523)	(1,628)
Net cash used in financing activities	(12,134)	(2,837)
Effect of exchange rate changes on cash	(320)	(38)
Decrease in cash and cash equivalents	(225)	(3,313)
Cash and cash equivalents at beginning of period	4,508	7,821
Cash and cash equivalents at end of period	4,283	4,508
Cash paid for interest	3,795	2,314
Cash paid for income taxes, net of refunds	$ 207	$ 534

Note 5 - Balance Sheet Information - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment, Gross	$ 18,366	$ 18,212
Less: accumulated depreciation	(14,385)	(14,846)
Property, plant and equipment, net	3,981	3,366
Machinery and Equipment [Member]
Property, Plant and Equipment, Gross	8,154	7,500
Computer Equipment and Software [member]
Property, Plant and Equipment, Gross	6,493	6,781
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross	2,417	2,507
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross	1,244	1,386
Automobiles [Member]
Property, Plant and Equipment, Gross	$ 58	$ 38

Note 7 - Employee Benefit Plans (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Costs of Retirement Plans [Table Text Block]

	Year Ended December 31,
(in thousands)	2023			2022
Interest cost	$	670		$	371
Expected return on plan assets		(788	)		(818	)
Net amortization loss		328			27
Net periodic benefit expense (credit)	$	210		$	(420	)

Schedule of Changes in Fair Value of Plan Assets [Table Text Block]

	December 31,
(in thousands)	2023			2022
Change in fair value of plan assets:
Balance at beginning of year	$	15,576		$	27,252
Actual return on plan assets		351			(9,098	)
Employer contributions		622			619
Benefits paid		(563	)		(592	)
Currency translation adjustment		954			(2,605	)
Balance at end of year	$	16,940		$	15,576

Schedule of Changes in Projected Benefit Obligations [Table Text Block]

	December 31,
(in thousands)	2023			2022
Change in benefit obligation:
Balance at beginning of year	$	13,263		$	22,562
Interest cost		665			371
Actuarial loss (gain)		479			(6,912	)
Benefits paid		(563	)		(592	)
Currency translation adjustment		819			(2,166	)
Balance at end of year	$	14,663		$	13,263

	December 31,
(in thousands)	2023		2022
Fair value of plan assets	$	16,940	$	15,576
Benefit obligation		14,663		13,263
Net funded status	$	2,277	$	2,313

Schedule of Amounts Recognized in Balance Sheet [Table Text Block]

	December 31,
(in thousands)	2023		2022
Other long-term assets	$	2,277	$	2,313
Accumulated other comprehensive loss		5,909		5,326

Defined Benefit Plan, Assumptions [Table Text Block]

	December 31,
(in thousands)	2023			2022
Discount rate		4.6	%		5.0	%
Expected return on assets		5.3	%		5.0	%

Schedule of Allocation of Plan Assets [Table Text Block]

(in thousands)	2023				2022
Asset category:
Debt securities	$	11,761	69	%	$	11,714	75	%
Equity securities		3,567	21	%		3,507	23	%
Cash and cash equivalents		304	2	%		185	1	%
Other		1,308	8	%		170	1	%
Total	$	16,940	100	%	$	15,576	100	%

Defined Benefit Plan, Plan Assets, Category [Table Text Block]

(in thousands)	2023		2022
Quoted Prices in Active Markets for Identical Assets (Level 1)	$	304	$	185
Significant Other Observable Inputs (Level 2)		16,636		15,391
Significant Other Unobservable Inputs (Level 3)		-		-
Total	$	16,940	$	15,576

Note 10 - Derivatives - The Effect of Derivatives Designated as Cash Flow Hedging Instruments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Amount of loss recognized in OCI on derivatives (effective portion)	$ 199
Amounts reclassified from accumulated other comprehensive loss to interest expense	$ 120

Insider Trading Arrangements

1 Months Ended

12 Months Ended

Dec. 31, 2023

Insider Trading Arr Line Items

Material Terms of Trading Arrangement [Text Block]

Item 9B.

Other Information.

On November 23, 2023, James Green, our Chairman, President and Chief Executive Officer, adopted a trading plan intended to satisfy the affirmative defense available under Rule 10b5-1(c) (the “Trading Plan”). The expiration date of the Trading Plan was February 7, 2025. The total number of shares of our common stock (the “Shares”) to be sold under the Trading Plan was a maximum of 240,000. Mr. Green terminated the Trading Plan on January 21, 2024. No Shares were sold under the Trading Plan prior to its termination.

Trading Arrangement Adoption Date

November 23, 2023

Trading Arrangement, Individual Name

James Green

Trading Arrangement, Individual Title

Chairman, President and Chief Executive Officer

Rule 10b5-1 Arrangement Adopted [Flag]

true

Non-Rule 10b5-1 Arrangement Adopted [Flag]

false

Trading Arrangement, Securities Aggregate Available Amount (in shares)

240,000

Rule 10b5-1 Arrangement Terminated [Flag]

false

Non-Rule 10b5-1 Arrangement Terminated [Flag]

false

Trading Arrangement Termination Date

January 21, 2024

Note 2 - Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2023

Significant Accounting Policies [Text Block]

2.	Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of Harvard Bioscience, Inc. and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires the use of management estimates. Such estimates include the determination and establishment of certain accruals and provisions, including those for income taxes, credit losses on receivables. and defined benefit pension obligations. Estimates are also required to evaluate the value for inventories reported at lower of cost or net realizable value, stock-based compensation expense, and the recoverability of long-lived and intangible assets, including goodwill. On an ongoing basis, the Company reviews its estimates based upon currently available information. Actual results could differ materially from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash holdings in financial institutions that exceed insured limits for such financial institutions. The Company mitigates this risk by utilizing financial institutions of high credit quality.

Approximately 49% of the Company’s cash and cash equivalents at December 31, 2023 was held by the Company’s foreign subsidiaries and subject to repatriation tax considerations. These foreign funds were held primarily by subsidiaries in the United Kingdom, Germany and Spain.

Marketable Equity Securities

Equity securities traded in active markets are marked to market at each balance sheet date based on prices as quoted on the relevant stock exchange. Fair value mark-to-market adjustments are recorded as non-operating gains (losses) in the consolidated statement of operations. The Company’s investments in marketable equity securities are classified in the consolidated balance sheet based on the nature of the securities and their availability for use in current operations.

Allowance for Expected Credit Losses on Receivables

The allowance for expected credit losses on receivables is used to present accounts receivable, net, at an amount that represents the Company’s estimate of the receivables expected to be collected from customers. The allowance represents an estimate of expected credit losses over the lifetime of the receivables, even if the loss is considered remote, and reflects expected recoveries of amounts previously written off. The Company estimates the allowance on the basis of specifically identified receivables that are evaluated individually for impairment and an analysis of the remaining receivables determined by reference to past default experience. The Company considers the need to adjust historical information to reflect the extent to which current conditions and reasonable forecasts are expected to differ from the conditions that existed for the historical period considered. Losses on receivables have not historically been significant.

Management judgments are used to determine when to charge off uncollectible trade accounts receivable. The Company bases these judgments on the age of the receivable, credit quality of the customer, current economic conditions, and other factors that may affect a customer’s ability and intent to pay. Customers are generally not required to provide collateral for purchases.

Inventories

The Company values inventories at the lower of cost (determined on a first-in, first-out method) or net realizable value. The Company regularly reviews inventory quantities on hand and writes down excess and obsolete inventories to estimated net realizable value if less than cost, based primarily on historical inventory usage and estimated forecast of product demand.

Property, Plant and Equipment

Property, plant and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets as follows:

Machinery and equipment (years)	3	-	10
Computer equipment and software (years)	3	-	7
Furniture and fixtures (years)	5	-	10

Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset.

Leases

The Company leases office space, manufacturing facilities, automobiles and equipment. The Company concludes on whether an arrangement is a lease at inception. This determination as to whether an arrangement contains a lease is based on an assessment as to whether a contract conveys the right for the Company to control the use of the identified property, plant or equipment for a period of time in exchange for consideration. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company recognizes these lease expenses on a straight-line basis over the lease term.

The Company has assessed its contracts and concluded that its leases consist of operating leases. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities, and operating lease liabilities in the Company’s consolidated balance sheets.

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the leases’ commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company determines an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate represents a significant judgment that is based on an analysis of the Company’s credit rating, country risk, treasury and corporate bond yields, as well as comparison to the Company’s borrowing rate on its most recent loan. The Company uses the implicit rate when readily determinable. The Company has lease agreements with lease and non-lease components, which are generally accounted for separately.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company uses the flow-through method to account for investment tax credits. Under this method, the investment tax credits are recognized as a reduction of income tax expense.

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is more than 50% likely of being realized. Changes in recognition are reflected in the period in which the judgement occurs. The Company’s policy is to account for Global Intangible Low-Taxed income as a period cost.

Foreign Currency

The functional currency of the Company’s foreign subsidiaries is generally their local currency. All assets and liabilities of foreign subsidiaries are translated at exchange rates in effect at period-end. Income and expenses are translated at rates which approximate those in effect on the transaction dates. The resulting translation adjustment is recorded as a separate component of stockholders’ equity in accumulated other comprehensive income (loss) (“AOCI”) in the consolidated balance sheets. Gains and losses resulting from foreign currency transactions are included in other expense (income), net, in the Company’s consolidated statements of operations.

Earnings per Share

Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the periods presented. The computation of diluted earnings per share is similar to the computation of basic earnings per share, except that the denominator is increased for the assumed exercise of dilutive options and other potentially dilutive securities using the treasury stock method unless the effect is antidilutive.

The following table sets forth the computation of basic and diluted earnings per share:

	Year Ended December 31,
(in thousands, except per share data)	2023			2022
Net loss	$	(3,415	)	$	(9,516	)
Weighted average shares outstanding - basic		42,420			41,413
Dilutive effect of equity awards		-			-
Weighted average shares outstanding - diluted		42,420			41,413
Basic loss per share	$	(0.08	)	$	(0.23	)
Diluted loss per share	$	(0.08	)	$	(0.23	)
Shares excluded from diluted loss per share due to their anti-dilutive effect		3,868			3,661

Comprehensive Income (Loss)

Comprehensive income (loss) represents the change in equity resulting from items other than shareholder investments and distributions. The Company’s foreign currency translation adjustments, interest rate swap - cash flow hedge and minimum pension liability adjustments are included in AOCI. The components of other comprehensive income are reclassified as net income, net of tax, when the underlying component impacts earnings. Comprehensive income (loss) and the components of AOCI are presented in the accompanying consolidated statements of comprehensive loss and consolidated statements of equity.

Revenue Recognition

Nature of contracts and customers

The Company’s contracts are primarily of short duration and are mostly based on the receipt and fulfilment of purchase orders. The purchase orders are binding and include pricing and all other relevant terms and conditions.

The Company’s customers are primarily research scientists at pharmaceutical and biotechnology companies, universities, hospitals, government laboratories and contract research organizations. The Company also has global and regional distribution partners, and original equipment manufacturer customers who incorporate its products into their products under their own brands.

Performance obligations

The Company’s performance obligations under its revenue contracts consist of its instruments, equipment, accessories, services, software licenses and enhancements, maintenance and extended warranties. Equipment also includes software that functions together with the tangible equipment to deliver its essential functionality. Contracts with customers may contain multiple promises such as delivery of hardware, software, professional services or post-contract support services. These promises are accounted for as separate performance obligations if they are distinct. For contracts with customers that contain multiple performance obligations, the transaction price is allocated to the separate performance obligations based on estimated relative standalone selling price, which does not materially differ from the stated price in the contract. In general, the Company’s list prices are indicative of standalone selling price, and the majority of the Company's contracts have a term of less than one year.

Instruments, equipment and accessories consist of a range of products that are used in life sciences research. Revenues from the sales of these items are recognized when transfer of control of these products to the customer occurs. Transfer of control occurs when the Company has a right to payment and the customer has legal title to the asset and the customer or their selected carrier has possession, which is typically upon shipment. Sales of these items are therefore generally recognized at a point in time.

The Company’s equipment revenue also includes the sale of wireless implantable monitors that are used for life science research purposes. The Company sells these wireless implantable monitors to pharmaceutical companies, contract research organizations and academic laboratories. In addition to sales generated from new and existing customers, these implantable devices are also sold under a program called the “exchange program.” Under this program, customers may return an implantable monitor to the Company after use, and if the returned monitor can be reprocessed and resold, they may, in exchange, purchase a replacement implantable monitor of the same model at a lower price than a new monitor. The implantable monitors that are returned by customers are reprocessed and made available for future sale. The initial sale of implantable monitors and subsequent sale of replacement implantable monitors are independent transactions. The Company has no obligation in connection with the initial sale to sell replacement implantable monitors at any future date under any fixed terms and may refuse returned implantable monitors that cannot be recovered or are obsolete. The Company has concluded that the offer to its customers that they may purchase a discounted product in the future is not a material right.

Service revenue consists of installation, training, data analysis and surgeries performed on research animals. Service revenue is recognized when the service is performed. Maintenance revenue consists of post-contract support provided in relation to software that is embedded within the equipment that is sold to the customer. The Company provides standard warranties that promise the customer that the product will work as promised and are not a separate performance obligation. Extended warranties relate to warranties that are separately priced and purchased in addition to a standard warranty, and are therefore a separate performance obligation. The Company has made the judgment that the customer benefits as the Company performs over the period of the contract, and therefore revenues from maintenance and warranty contracts are recognized over time. The Company uses the input method to recognize revenue over time, which is generally on a straight-line basis over the service period.

For sales for which transfer of control occurs upon shipment, the Company accounts for shipping and handling costs as fulfilment costs. As such, the Company records the amounts billed to the customer for shipping costs as revenue and the costs within cost of revenues upon shipment. For sales, for which control transfers to customers after shipment, the Company has elected to account for shipping and handling as activities to fulfill the promise to transfer the goods to the customer. The Company therefore accrues for the costs of shipping undelivered items in the period of shipment.

Variable Consideration

The nature of the Company's contracts gives rise to certain types of variable consideration, including in limited cases volume and payment discounts. The Company analyzes sales that could include variable consideration and estimates the expected or most likely amount of revenue after returns, trade-ins, discounts, rebates, credits, and incentives. Product returns are estimated and accrued for, based on historical information. In making these estimates, the Company considers whether the amount of variable consideration is constrained and is included in revenue only to the extent that it is probable that a significant reversal of the revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration, and its impact on the Company’s revenue recognition, was not material in any of the periods presented.

The Company’s payment terms are generally from zero to sixty days from the time of invoicing, which occurs at the time of shipment or prior to services being performed. Payment terms vary by the type of customers and the products or services offered.

Sales taxes, value added taxes, and certain excise taxes collected from customers and remitted to governmental authorities are accounted for on a net basis and are therefore excluded from revenues.

Contract Liabilities

The Company records contract liabilities when cash is collected from customers prior to satisfaction of the Company’s performance obligation to the customer. Contract liabilities consist of amounts deferred related to service contracts and revenue deferred as a result of payments received in advance from customers. Contract liabilities are generally expected to be recognized within one year.

The amounts included in contract liabilities from advanced payments relate to amounts that are prepaid for wireless implantable monitors under the exchange program. The Company has made the judgment that these payments do not represent a significant financing component as the customer can exercise their discretion as to when they can obtain the products for which they have made a prepayment.

Disaggregation of revenue

Refer to Note 13 for revenue disaggregated by type and by geographic location as well as further information about the deferred revenue balances.

Software Development

Software development costs for software products to be sold, leased or otherwise marketed that are incurred before establishing technological feasibility are charged to operations. Software development costs incurred after establishing technological feasibility are capitalized on a product-by-product basis until the product is available for general release to customers at which time amortization begins.

Annual amortization, charged to cost of goods sold, is the amount computed using the ratio that current revenues for a product bear to the total current and anticipated future revenues for that product. In the event that future revenues are not estimable, such costs are amortized on a straight-line basis over the remaining estimated economic life of the product.

Intangible Assets

Intangible assets are comprised of existing technology, customer contracts and contractual relationships, and other definite-lived intangible assets. Identifiable intangible assets resulting from the acquisitions of entities accounted for using the purchase method of accounting are estimated by the Company based on the fair value of assets received. Identifiable definite-lived intangible assets are being amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from four to fifteen years.

Goodwill

Goodwill acquired in a business combination and determined to have an indefinite useful life is not amortized, but instead is tested for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired.

For the purpose of its goodwill analysis, the Company has one reporting unit. The Company conducts its annual impairment analysis in the fourth quarter of the fiscal year and more frequently if there is an indicator of impairment. The Company assesses qualitative factors of the reporting unit to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. If the qualitative assessment indicates a potential impairment, a quantitative analysis is performed. The Company compares the fair value of the reporting unit with its carrying amount. The Company typically estimates fair value using the income approach but will also consider market approaches when appropriate. Under the income approach, the Company uses a discounted cash flows model, which indicates the fair value of the reporting unit based on the present value of the cash flows that the Company expects the reporting unit to generate in the future. The Company's significant estimates in the discounted cash flows model include weighted average cost of capital, long-term rate of growth and profitability of the reporting unit, expected income tax rates and working capital effects. If the carrying amount of a reporting unit exceeds its fair value, goodwill is impaired, and the Company would recognize a loss equal to the excess.

The Company evaluated its goodwill for impairment as of October 1, 2023 by performing a qualitative analysis and determined that it was more likely than not that the fair value of the reporting unit exceeded the carrying value.

Impairment of Long-Lived Assets

The Company assesses recoverability of its long-lived assets that are held for use, such as property, plant and equipment and amortizable intangible assets when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Factors which could trigger an impairment review include significant negative industry or economic trends, significant loss of clients, and significant changes in the manner of the Company’s use of the assets or the strategy for its overall business.

The recoverability of assets or an asset group to be held and used is measured by a comparison of the carrying amount of an asset or asset group to estimated undiscounted future cash flows expected to be generated by the asset or the asset group. Cash flow projections are based on trends of historical performance and management’s estimate of future performance. The Company’s estimate of future cash flows requires significant judgment based on historical and anticipated results and are subject to many factors.

When the Company determines that the carrying value of the assets may not be recoverable based upon the existence of one or more of the above indicators of impairment, the Company measures the potential impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in its current business model. An impairment loss is recognized only if the carrying amount of the asset is not recoverable and exceeds its fair value. Different assumptions and judgments could materially affect the calculation of the fair value of our assets. For the years ended December 31, 2023 and 2022, the Company concluded that there were no triggering events requiring the Company to assess the recoverability of its long-lived assets.

Derivatives

The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company only enters into derivative contracts that it intends to designate as a hedge of a forecasted transaction or the variability of cash flows to be received or paid related to a recognized asset or liability (cash flow hedge) and does not use derivative financial instruments for trading or speculative purposes. The Company recognizes all derivative instruments as either assets or liabilities in the balance sheet at their respective fair values.

The Company formally documents the hedging relationship and its risk-management objective and strategy for undertaking the hedge, the hedging instrument, the hedged transaction, the nature of the risk being hedged, how the hedging instrument’s effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness. For derivative instruments that are designated and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income (loss) (“OCI”) and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.

By using derivative financial instruments to hedge exposure to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is negative, the Company owes the counterparty and, therefore, the Company is not exposed to the counterparty’s credit risk in those circumstances. The Company minimizes counterparty credit risk in derivative instruments by entering into transactions with major financial institutions based upon their credit profile. Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest-rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken. The Company monitors interest rate risk attributable to both its outstanding and forecasted debt obligations by the use of cash flow sensitivity analysis, which estimates the expected impact of changes in interest rates on the Company’s future cash flows.

Fair Value of Financial Instruments

Financial reporting standards define a fair value hierarchy that consists of three levels:

●

Level 1 includes instruments for which quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.

●

Level 2 includes instruments for which the valuations are based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.

●

Level 3 includes valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The carrying values of the Company’s cash and cash equivalents, trade accounts receivable, trade accounts payable and short-term debt approximate their fair values because of the short maturities of those instruments. The fair value of the Company’s long-term debt approximates its carrying value and is based on the amount of future cash flows associated with the debt discounted using current borrowing rates for similar debt instruments of comparable maturity (Level 2).

Stock-based Compensation

The Company recognizes compensation expense for all stock-based payment awards made to employees and directors including stock options, restricted stock units, and restricted stock units with a market condition. The Company issues awards under the 2021 Incentive Plan (the “2021 Incentive Plan”) and the Fourth Amended and Restated 2000 Stock Option and Incentive Plan (the “2000 Incentive Plan” and together with the 2021 Incentive Plan, the “Incentive Plans”), as well as issues shares for employee stock purchases related to its Employee Stock Purchase Plan (as amended, the “ESPP”). The Company issues new shares from its registered but unissued stock pool to satisfy stock option exercises and vesting of the restricted stock units. Stock-based compensation expense is recorded on a straight-line basis over the applicable service period, which ranges from one to four years. The Company has elected as an accounting policy to account for forfeitures for service-based awards as they occur, with no adjustment for estimated forfeitures.

The fair value of restricted stock units is based on the market price of the Company’s stock on the date of grant. The Company values restricted stock units with a market condition using a Monte-Carlo valuation simulation. The determination of fair value of stock-based payment awards on the date of grant using a Monte-Carlo valuation simulation is affected by the Company’s stock price as well as assumptions regarding certain variables including, but are not limited to, the Company’s expected stock price volatility over the term of the awards, interest rate assumptions, and discounts to adjust for any holding period post-vest restrictions.

Preferred Stock

The Company’s board of directors has the authority to issue up to 5.0 million shares of preferred stock and to determine the price privileges and other terms of the shares. The board of directors may exercise this authority without any further approval from stockholders. As of December 31, 2023 and 2022, the Company had no preferred stock issued or outstanding.

Business Segment Information

The Company operates in one segment which involves the design, development, production and distribution of products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. The Company has a single, company-wide management team that administers all properties as a whole rather than as discrete operating segments. The chief operating decision maker, who is the Company's chief executive officer, measures financial performance as a single enterprise and allocates resources across the Company to maximize profitability, and not on geography, legal entity, or end market basis. The Company operates in a number of countries throughout the world in a variety of product lines. Information regarding product lines and geographic financial information is provided in Note 13, “Revenues” and Note 5, "Balance Sheet Information."

Commitments and Contingencies

Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. If a loss is reasonably possible and the loss or range of loss can be reasonably estimated, the Company discloses the possible loss. If a loss is probable and the loss or range of loss cannot be reasonably estimated, the Company discloses or states that such an estimate cannot be made. Refer to Note 15 Commitments and Contingencies for additional information. The Company accrues and expenses legal costs associated with contingencies when incurred.

Recent Accounting Pronouncements

Accounting Pronouncements Adopted in 2023

In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment (ASU 2017-04), which eliminates the performance of Step 2 from the goodwill impairment test. In performing its annual or interim impairment testing, an entity will instead compare the fair value of the reporting unit with its carrying amount and recognize any impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss. The Company adopted ASU 2017-04 effective January 1, 2023, with no impact to the consolidated financial statements.

In September 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU 2016-13), which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. The FASB issued several ASUs after ASU 2016-13 to clarify implementation guidance and to provide transition relief for certain entities. The Company adopted ASU 2016-13 effective January 1, 2023, which resulted in an immaterial impact to the consolidated financial statements.

Accounting Pronouncements yet to be Adopted

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax, which enhances disclosures related to the effective tax rate reconciliation, income taxes paid, as well as other disclosures. The new standard impacts footnote disclosures and is effective for the Company’s annual financial statements for the year ended December 31, 2025. The Company is currently evaluating the potential impact of adopting ASU 2023-09 will have on the disclosures in its consolidated financial statements.

Prior Period Financial Statement Reclassifications

During the year ended December 31, 2023, the Company identified immaterial misclassification errors in the financial statement footnote describing the components of AOCI as of December 31, 2022 and 2021. These misclassifications overstated the amount attributed to the defined benefit pension plans, net of tax, by $5.4 million and $5.1 million and understated the amount attributed to foreign currency translation adjustments by $(5.4) million and $(5.1) million as of December 31, 2022 and 2021, respectively. These misclassifications had no impact on total OCI for the year ended December 31, 2022, included in the consolidated statements of comprehensive loss, or the total AOCI included in the consolidated balance sheets as of December 31, 2022, and also had no impact on any of the Company’s previously reported consolidated statements of operations, stockholders’ equity, or cash flows. The correction of these offsetting misclassifications is included in these consolidated financial statements. See Note 3 below for further details.

Note 17 - Product Line Disposition

12 Months Ended

Dec. 31, 2023

Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]

17.

Product Line Disposition

On February 17, 2023, the Company completed the disposition of its Hoefer product line for cash consideration of $0.5 million. The carrying value of assets sold was $0.1 million resulting in a gain on disposition of $0.4 million which is recorded in other (expense) income, net, in the consolidated statement of operations for the year ended December 31, 2023. Revenue and gross profit of this disposed product line included in the condensed consolidated statement of operations for the years ended December 31, 2023 and 2022, were not significant.

Note 6 - Restructuring and Other Exit Costs (Tables)

12 Months Ended

Dec. 31, 2023

Restructuring and Related Costs [Table Text Block]

(in thousands)	Inventory Related			Severance			Other			Total
Balance at December 31, 2021	$	-		$	-		$	-		$	-
Restructuring and other exit costs		1,471			877			46			2,394
Non-cash charges		(1,471	)		-			-			(1,471	)
Cash payments		-			(241	)		(46	)		(287	)
Balance at December 31, 2022		-			636			-			636
Restructuring and other exit costs		320			42			29			391
Non-cash charges		(142	)		-			-			(142	)
Cash payments		(94	)		(678	)		(29	)		(801	)
Balance at December 31, 2023	$	84		$	-		$	-		$	84

Note 12 - Stock-Based Compensation - Black Scholes Assumptions (Details) - Black Scholes Option Pricing Model [Member] - Share-Based Payment Arrangement, Option [Member]	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Volatility	56.80%	62.60%
Risk-free interest rate	4.60%	2.10%
Correlation coefficient	41.70%	41.50%
Dividend yield	0.00%	0.00%
Liquidity discount	14.10%	11.70%

Note 16 - Litigation Settlement (Details Textual) - USD ($) $ in Millions		12 Months Ended
	Jun. 10, 2022	Dec. 31, 2023	Dec. 31, 2022
Equity Securities without Readily Determinable Fair Value, Amount	$ 3.9
Preferred Stock, Book Value, Inclusive of Accrued Dividends			$ 4.1
Harvard Apparatus Regenerative Technology, Inc. (“HART”) [Member]
Investment Owned, Fair Value		$ 3.5
Equity Securities, FV-NI, Unrealized Gain (Loss)		$ 0.6
Case in Suffolk Superior Court [Member] \| Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Issued For Settlement (in shares)	4,000
Stock Issued During Period, Value, Issued for Settlement	$ 4.0

Fair value of investment in security owned.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480493/946-210-55-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-2

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(11))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(2)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(2)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6

Note 2 - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)	Dec. 31, 2023
Machinery and Equipment [Member] \| Minimum [Member]
Property, plant and equipment useful life (Year)	3 years
Machinery and Equipment [Member] \| Maximum [Member]
Property, plant and equipment useful life (Year)	10 years
Computer Equipment and Software [member] \| Minimum [Member]
Property, plant and equipment useful life (Year)	3 years
Computer Equipment and Software [member] \| Maximum [Member]
Property, plant and equipment useful life (Year)	7 years
Furniture and Fixtures [Member] \| Minimum [Member]
Property, plant and equipment useful life (Year)	5 years
Furniture and Fixtures [Member] \| Maximum [Member]
Property, plant and equipment useful life (Year)	10 years

Note 8 - Leases

12 Months Ended

Dec. 31, 2023

Lessee, Operating Leases [Text Block]

8.	Leases

The Company has noncancelable operating leases for office space, manufacturing facilities, warehouse space, automobiles and equipment expiring at various dates through 2030.

The components of lease expense for the years ended December 31, 2023 and 2022, are as follows:

	Year Ended December 31,
(in thousands)	2023			2022
Operating lease cost	$	2,013		$	1,971
Short-term lease cost		199			233
Sublease income		(102	)		(102	)
Total lease cost	$	2,110		$	2,102

Supplemental balance sheet information related to the Company’s operating leases was as follows:

(in thousands)	December 31,
	2023			2022
Operating lease right-of-use assets	$	4,773		$	5,816

Current portion, operating lease liabilities		1,416			2,135
Operating lease liabilities, long-term		4,794			5,282
Total operating lease liabilities	$	6,210		$	7,417

Weighted average remaining lease term (years)		5.7			6.2
Weighted average discount rate		9.5	%		9.4	%

Supplemental cash flow information related to the Company’s operating leases was as follows:

	Year Ended December 31,
(in thousands)	2023		2022
Cash paid for amounts included in the measurement of lease liabilities	$	2,367	$	2,347
Right-of-use assets obtained in exchange for lease obligations		293		295

Future minimum lease payments for operating leases, with initial terms in excess of one year at December 31, 2023, are as follows:

Year Ending December 31,
(in thousands)
2024		1,938
2025		1,166
2026		1,060
2027		1,047
2028		1,057
Thereafter		1,926
Total lease payments		8,194
Less imputed interest		(1,984	)
Total operating lease liabilities	$	6,210

Note 14 - Income Tax (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Effective Income Tax Rate Reconciliation, Percent, Total	(33.50%)	(3.70%)
Research and Development Tax Credit Carryforwards Offset by Reserve for Uncertain Tax Positions	$ 800
Deferred Tax Assets, Tax Credit Carryforwards, Total	2,700
Deferred Tax Assets, Valuation Allowance	15,222	$ 14,506
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	700	200
Cash and Cash Equivalents, at Carrying Value, Total	4,283	4,508
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	400
Non-US [Member] \| Subsidiaries [Member]
Cash and Cash Equivalents, at Carrying Value, Total	2,100	$ 2,600
Expire 2024 [Member]
Deferred Tax Assets, Tax Credit Carryforwards, Research	7,800
State and Local Jurisdiction [Member] \| Expire between 2024 and 2043 [Member]
Operating Loss Carryforwards	6,300
Foreign Tax Authority [Member]
Operating Loss Carryforwards	7,800
Foreign Tax Authority [Member] \| Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	$ 400

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($)
Percentage of Cash and Cash Equivalents Held by Foreign Subsidiaries	49.00%
Goodwill, Impairment Loss	$ 0
Impairment of Long-Lived Assets Held-for-use	$ 0
Preferred Stock, Shares Authorized (in shares) \| shares	5,000,000	5,000,000
Preferred Stock, Shares Issued (in shares) \| shares	0	0
Preferred Stock, Shares Outstanding (in shares) \| shares		0
Number of Operating Segments	1
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	$ 446	$ 2,411
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	1,507	(2,614)
Other Comprehensive Income (Loss), Net of Tax	862	(5,025)
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (14,190)	(15,052)
Revision of Prior Period, Adjustment [Member]
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax		5,400	$ 5,100
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax		5,400	$ 5,100
Other Comprehensive Income (Loss), Net of Tax		0
Accumulated Other Comprehensive Income (Loss), Net of Tax		$ 0
Minimum [Member]
Customer Payments Term (Day)	0 days
Finite-Lived Intangible Asset, Useful Life (Year)	4 years
Minimum [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	1 year
Maximum [Member]
Customer Payments Term (Day)	60 days
Finite-Lived Intangible Asset, Useful Life (Year)	15 years
Maximum [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	4 years

Note 7 - Employee Benefit Plans - Recognized in Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Other long-term assets	$ 5,909	$ 5,326
Other Noncurrent Liabilities [Member]
Other long-term assets	$ 2,277	$ 2,313

Note 11 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Recurring [Member] $ in Thousands	Dec. 31, 2023 USD ($)
Equity securities - common stock	$ 3,511
Interest Rate Swap [Member]
Derivative liabilities	(199)
Fair Value, Inputs, Level 1 [Member]
Equity securities - common stock	3,511
Fair Value, Inputs, Level 1 [Member] \| Interest Rate Swap [Member]
Derivative liabilities	0
Fair Value, Inputs, Level 2 [Member]
Equity securities - common stock	0
Fair Value, Inputs, Level 2 [Member] \| Interest Rate Swap [Member]
Derivative liabilities	(199)
Fair Value, Inputs, Level 3 [Member]
Equity securities - common stock	0
Fair Value, Inputs, Level 3 [Member] \| Interest Rate Swap [Member]
Derivative liabilities	$ 0

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480524/946-210-50-6

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(9)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G)(Footnote 8))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5C
-Subparagraph (SX 210.12-13C(Column H))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13(Column G))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5A
-Subparagraph (SX 210.12-13A(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 5B
-Subparagraph (SX 210.12-13B(Column E)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483466/210-20-50-3

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-22

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483444/210-20-55-10

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-10

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 4,283	$ 4,508
Accounts receivable, net	16,099	16,705
Inventories	24,716	26,439
Other current assets	3,940	3,472
Total current assets	49,038	51,124
Property, plant and equipment, net	3,981	3,366
Operating lease right-of-use assets	4,773	5,816
Goodwill	57,065	56,260
Intangible assets, net	16,036	21,014
Other long-term assets	6,473	7,780
Total assets	137,366	145,360
Current liabilities:
Current portion of long-term debt	5,859	3,811
Current portion of operating lease liabilities	1,416	2,135
Accounts payable	5,554	6,447
Contract liabilities	4,508	3,370
Other current liabilities	9,205	7,486
Total current liabilities	26,542	23,249
Long-term debt, net	30,704	43,013
Deferred tax liability	776	590
Operating lease liabilities	4,794	5,282
Other long-term liabilities	1,476	1,006
Total liabilities	64,292	73,140
Commitments and contingencies - Note 15
Stockholders' equity:
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized	0	0
Common stock, par value $0.01 per share, 80,000,000 shares authorized: 43,394,509 shares issued and outstanding at December 31, 2023; 42,081,707 shares issued and outstanding at December 31, 2022	434	454
Additional paid-in-capital	232,435	229,008
Accumulated deficit	(145,605)	(142,190)
Accumulated other comprehensive loss	(14,190)	(15,052)
Total stockholders' equity	73,074	72,220
Total liabilities and stockholders' equity	$ 137,366	$ 145,360

Note 9 - Long-term Debt

12 Months Ended

Dec. 31, 2023

Long-Term Debt [Text Block]

9.	Long-Term Debt

As of December 31, 2023 and 2022, the Company’s borrowings were comprised of the following:

(in thousands)	December 31, 2023			December 31, 2022
Long-term debt:
Term loan	$	30,723		$	34,814
Revolving line		6,400			12,850
Less: unamortized deferred financing costs		(560	)		(840	)
Total debt		36,563			46,824
Less: current portion of long-term debt		(6,139	)		(4,091	)
Current unamortized deferred financing costs		280			280
Long-term debt	$	30,704		$	43,013

The aggregate amounts of debt maturities are as follows:

(in thousands)
2024	$	6,139
2025		30,984
	$	37,123

On December 22, 2020, the Company entered into a Credit Agreement (the “Credit Agreement”) with Citizens Bank, N.A., Wells Fargo Bank, National Association, and Silicon Valley Bank, (together, the “Lenders”). Effective March 27, 2023, all commitments and obligations under the Credit Agreement previously held by Silicon Valley Bank were assumed by First Citizens Bank & Trust Company. The Credit Agreement provides for a term loan of $40.0 million and a $25.0 million senior revolving credit facility (including a $10.0 million sub-facility for the issuance of letters of credit and a $10.0 million swingline loan sub-facility) (collectively, the “Credit Facility”). The Company’s obligations under the Credit Agreement are guaranteed by certain of the Company’s direct, domestic wholly-owned subsidiaries; none of the Company’s direct or indirect foreign subsidiaries has guaranteed the Credit Facility. The Company’s obligations under the Credit Agreement are secured by substantially all of the assets of Harvard Bioscience, Inc. and each guarantor (including all or a portion of the equity interests in certain of the Company’s domestic and foreign subsidiaries). The Credit Facility matures on December 22, 2025. Issuance costs of $1.4 million are amortized over the contractual term to maturity date on a straight-line basis, which approximates the effective interest method. Available and unused borrowing capacity under the revolving line of credit was $10.8 million as of December 31, 2023, based on the Credit Agreement, as amended pursuant to the April 2022 Amendment and November 2022 Amendment as described below. Total revolver borrowing capacity is limited by the consolidated net leverage ratio as defined under the amended Credit Agreement.

Borrowings under the amended Credit Facility will, at the option of the Company, bear interest at either (i) a rate per annum based on the Secured Overnight Financing Rate (“SOFR”) for an interest period of one, two, three or six months, plus an applicable interest rate margin determined as provided in the Credit Agreement, as amended (a “SOFR Loan”), or (ii) an alternative base rate plus an applicable interest rate margin, each as determined as provided in the Credit Agreement (an “ABR Loan”). SOFR interest under the Credit Agreement is subject to applicable market rates and a floor of 0.50%. The alternative base rate is based on the Citizens Bank prime rate or the federal funds effective rate of the Federal Reserve Bank of New York and is subject to a floor of 1.0%. The applicable interest rate margin varies from 2.0% per annum to 3.25% per annum for SOFR Loans, and from 1.5% per annum to 3.0% per annum for ABR Loans, in each case depending on the Company’s consolidated leverage ratio and is determined in accordance with a pricing grid set forth in the Credit Agreement. Interest on SOFR Loans is payable in arrears on the last day of each applicable interest period, and interest on ABR Loans is payable in arrears at the end of each calendar quarter. There are no prepayment penalties in the event the Company elects to prepay and terminate the Credit Facility prior to its scheduled maturity date, subject to SOFR Loan breakage and redeployment costs in certain circumstances.

The effective interest rate on the Company’s borrowings for the years ended December 31, 2023 and 2022, was 8.1% and 5.0%, respectively. The weighted average interest rate as of December 31, 2023, inclusive of the effect of the Company’s interest rate swaps, was 7.4%. The carrying value of the debt approximates fair value because the interest rate under the obligation approximates market rates of interest available to the Company for similar instruments.

As of December 31, 2023, the term loan amortizes in quarterly installments of $1.0 million with a balloon payment at maturity. Furthermore, within ninety days after the end of the Company’s fiscal year, the term loans may be permanently reduced pursuant to certain mandatory prepayment events including an annual “excess cash flow sweep”, as defined in the agreement; provided that, in any fiscal year, any voluntary prepayments of the term loans shall be credited against the Company’s “excess cash flow” prepayment obligations on a dollar-for-dollar basis for such fiscal year. As of December 31, 2023, the current portion of long-term debt includes an excess cash flow sweep of $2.1 million to be paid by March 31, 2024. As of December 31, 2022, the current portion of long-term debt included an excess cash flow sweep of $1.1 million which was paid on March 31, 2023. Amounts outstanding under the revolving credit facility can be repaid at any time but are due in full at maturity.

The Credit Agreement, as amended, includes customary affirmative, negative, and financial covenants binding on the Company. The negative covenants limit the ability of the Company, among other things, to incur debt, incur liens, make investments, sell assets and pay dividends on its capital stock. The financial covenants include a maximum consolidated net leverage ratio and a minimum consolidated fixed charge coverage ratio. The Credit Agreement, as amended, also includes customary events of default.

In April 2022, the Company entered into an amendment to the Credit Agreement (the “April 2022 Amendment”) which modified, among other things, the financial covenant relating to the consolidated net leverage ratio, and provided consent for the HRGN Settlement (as defined in Note 16). In November 2022, the Company entered into a subsequent amendment to the Credit Agreement which modified, among other things, the financial covenant relating to the consolidated net leverage ratio, and the definition of Consolidated EBITDA used in the calculation of certain financial covenants (the “November 2022 Amendment”). The Company was in compliance with the covenants of the Credit Agreement, as amended, as of December 31, 2023.

Note 12 - Stock-Based Compensation - Stock-Based Payment Awards (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Outstanding at December 31, 2021 (in shares)	1,238,776	1,404,816
Outstanding at December 31, 2021 (in dollars per share)	$ 3.15	$ 3.1
Exercised (in shares)	(213,644)	(40,267)
Exercised (in dollars per share)	$ 2.38	$ 2.64
Cancelled/Forfeited (in shares)	(101,065)	(125,773)
Cancelled/Forfeited (in dollars per share)	$ 2.71	$ 2.77
Outstanding at December 31, 2022 (in shares)	924,067	1,238,776
Outstanding at December 31, 2022 (in dollars per share)	$ 3.37	$ 3.15
Outstanding and Exerciseable at December 31, 2023 (Year)	3 years 4 months 24 days
Outstanding and Exerciseable at December 31, 2023	$ 1,836

Note 8 - Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash paid for amounts included in the measurement of lease liabilities	$ 2,367	$ 2,347
Right-of-use assets obtained in exchange for lease obligations	$ 293	$ 295

Note 14 - Income Tax - Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Federal and state	$ 570	$ 641
Foreign	61	194
current income tax (benefit) expense	631	835
Federal and state	132	(468)
Foreign	96	(30)
deferred income tax (benefit) expense	228	(498)
Total income tax expense (benefit)	$ 859	$ 337

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

Note 16 - Litigation Settlement

12 Months Ended

Dec. 31, 2023

Legal Matters and Contingencies [Text Block]

16.

Litigation Settlement

In April 2022, the Company and HRGN entered into a settlement of a litigation related to injuries allegedly caused by products produced by the Company and HRGN and utilized in connection with surgeries performed by third parties (the “HRGN Settlement”). The HRGN Settlement resolved and dismissed all claims by and between the parties. HRGN has indemnified the Company for all losses and expenses that the Company incurred in connection with such litigation and settlement.

In connection with the HRGN Settlement, in June 2022, HRGN issued 4,000 shares of Series E Convertible Preferred Stock (the “Series E Preferred Stock”) to the Company in satisfaction of $4.0 million of its total indemnification obligations. The Company recorded the Series E Preferred Stock at an estimated fair value of $3.9 million using a Monte Carlo valuation simulation incorporating information from selected guideline companies. As of December 31, 2022, the book value of the shares of Series E Preferred Stock, inclusive of accrued dividends, was $4.1 million and was included in the consolidated balance sheet as a component of other long-term assets.

In April 2023, all of the shares of Series E Preferred Stock the Company held in HRGN were mandatorily converted into shares of HRGN common stock.

As of December 31, 2023, the Company held shares of HRGN common stock with an estimated fair value of $3.5 million, which are included in the consolidated balance sheet as a component of other long-term assets. During the year ended December 31, 2023, the Company recorded an unrealized loss related to these shares of $(0.6) million, which was recorded as other (expense) income, net, in the consolidated statements of operations. The Company determines the fair value of its HRGN common stock based on the closing price as quoted on the OTCQB Marketplace at the reporting date. Due to HRGN’s limited operating history, its overall financial condition and the limited trading volumes and liquidity of its common stock, the value of the Company’s investment in this common stock could fluctuate considerably or become worthless.

Consolidated Statements of Comprehensive Loss (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Tax Benefit	$ 137	$ 566
Tax	$ 0	$ 0

Note 8 - Leases - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
2024	$ 1,938
2025	1,166
2026	1,060
2027	1,047
2028	1,057
Thereafter	1,926
Total lease payments	8,194
Less imputed interest	(1,984)
Total operating lease liabilities	$ 6,210	$ 7,417

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 112,250	$ 113,335
Cost of revenues	46,179	52,516
Gross profit	66,071	60,819
Sales and marketing expenses	24,108	25,041
General and administrative expenses	22,780	24,493
Research and development expenses	11,764	12,329
Amortization of intangible assets	5,525	6,122
Litigation settlement - Note 16	0	(233)
Total operating expenses	64,177	67,752
Operating income (loss)	1,894	(6,933)
Other (expense) income:
Interest expense	(3,591)	(2,548)
Unrealized loss on equity securities - Note 16	(632)	0
Other (expense) income, net	(227)	302
Total other expense	(4,450)	(2,246)
Loss before income taxes	(2,556)	(9,179)
Income tax expense	859	337
Net loss	$ (3,415)	$ (9,516)
Loss per share:
Basic and diluted loss per share (in dollars per share)	$ (0.08)	$ (0.23)
Weighted-average common shares:
Basic and diluted (in shares)	42,420	41,413

Note 8 - Leases (Tables)

12 Months Ended

Dec. 31, 2023

Lease, Cost [Table Text Block]

	Year Ended December 31,
(in thousands)	2023			2022
Operating lease cost	$	2,013		$	1,971
Short-term lease cost		199			233
Sublease income		(102	)		(102	)
Total lease cost	$	2,110		$	2,102

Supplemental Balance Sheet Informaton Related to Operating Leases [Table Text Block]

(in thousands)	December 31,
	2023			2022
Operating lease right-of-use assets	$	4,773		$	5,816

Current portion, operating lease liabilities		1,416			2,135
Operating lease liabilities, long-term		4,794			5,282
Total operating lease liabilities	$	6,210		$	7,417

Weighted average remaining lease term (years)		5.7			6.2
Weighted average discount rate		9.5	%		9.4	%

Supplemental Cash Flow Information Related to Operating Leases [Table Text Block]

	Year Ended December 31,
(in thousands)	2023		2022
Cash paid for amounts included in the measurement of lease liabilities	$	2,367	$	2,347
Right-of-use assets obtained in exchange for lease obligations		293		295

Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]

Year Ending December 31,
(in thousands)
2024		1,938
2025		1,166
2026		1,060
2027		1,047
2028		1,057
Thereafter		1,926
Total lease payments		8,194
Less imputed interest		(1,984	)
Total operating lease liabilities	$	6,210

Note 12 - Stock-Based Compensation

12 Months Ended

Dec. 31, 2023

Shareholders' Equity and Share-Based Payments [Text Block]

12.

Stock-Based Compensation

Stock-based compensation expense for the years ended December 31, 2023 and 2022, is allocated as follows:

	Year Ended December 31,
(in thousands)	2023		2022
Cost of revenues	$	308	$	121
Sales and marketing expenses		746		557
General and administrative expenses		3,560		3,487
Research and development expenses		386		246
Total stock-based compensation expenses	$	5,000	$	4,411

As of December 31, 2023, the total compensation costs related to unvested awards not yet recognized is $4.7 million and the weighted average period over which it is expected to be recognized is approximately 1.6 years. During the years ended December 31, 2023 and 2022, the Company did not capitalize any stock-based compensation.

Equity Incentive Plans

During 2021, the Company’s board of directors and stockholders adopted the 2021 Incentive Plan which authorized additional shares available for grants to officers, employees, non-employee directors and other key persons of the Company and its subsidiaries. As of December 31, 2023, there were approximately 3.1 million shares available for issuance under the 2021 Incentive Plan.

Restricted Stock Units with a Market Condition

The Company grants deferred awards of market condition restricted stock units (the “Market Condition RSUs”) to certain members of the Company’s management team. The vesting of the Market Condition RSUs is linked to the achievement of a relative total shareholder return (“TSR”) of the Company’s common stock measured from the earlier of (i) the measurement period as set out in the award agreement or (ii) upon a change of control (measured relative to the Nasdaq Biotechnology or Russell 2000 index and based on a 20-day trading average price) and is subject to a one-year holding period after vesting.

For Market Condition RSUs with a measurement period that concluded during the years ended December 31, 2023, the TSR of the Company’s common stock relative to the applicable index resulted in achieving 100% of the target. Market Condition RSUs outstanding as of December 31, 2023 remain subject to a TSR measurement which can result in vesting rates ranging from 0% to 150% of the target number.

The weighted average assumptions used in the valuation of the Market Condition RSUs granted during the years ended December 31, 2023 and 2022, are as follows:

	2023			2022
Volatility		56.8	%		62.6	%
Risk-free interest rate		4.6	%		2.1	%
Correlation coefficient		41.7	%		41.5	%
Dividend yield		-	%		-	%
Liquidity discount		14.1	%		11.7	%

The Company used historical volatility to calculate the expected volatility matching the expected holding period. The risk-free interest rate assumption is based upon observed U.S. Treasury bill interest rates (risk-free) appropriate for the term of the award. Additionally, the Company assumes a liquidity discount to adjust the fair value for the one-year holding period post-vest restrictions.

Stock-Based Payment Awards

RSU and Market Condition RSU activity for the years ended December 31, 2023 and 2022, is as follows:

						Condition
	*Restricted*			*Grant Date*		*Restricted*			*Grant Date*
	*Stock Units*			*Fair Value*		*Stock Units*			*Fair Value*
Balance at December 31, 2021		1,141,164		$	3.57		860,155		$	3.13
Granted		918,870			4.64		320,272			5.08
Vested		(733,611	)		4.08		(401,308	)		2.11
Cancelled/Forfeited		(232,622	)		4.44		(132,884	)		4.21
Balance at December 31, 2022		1,093,801		$	3.94		646,235		$	4.51
Granted		1,350,125			2.87		558,958			2.61
Vested		(1,144,065	)		3.38		(316,210	)		4.01
Cancelled/Forfeited		(134,865	)		3.71		(87,138	)		4.64
Balance at December 31, 2023		1,164,996		$	3.28		801,845		$	3.37

Stock option activity for the years ended December 31, 2023 and 2022, is as follows:

	Number of Options			Weighted-Average Exercise Price		Weighted-Aveage Remaining Contractual Term (years)		Average Intrinsic Value (in thousands)
Outstanding at December 31, 2021		1,404,816		$	3.10
Exercised		(40,267	)		2.64
Cancelled/Forfeited		(125,773	)		2.77
Outstanding at December 31, 2022		1,238,776		$	3.15
Exercised		(213,644	)		2.38
Cancelled/Forfeited		(101,065	)		2.71
Outstanding and Exerciseable at December 31, 2023		924,067		$	3.37		3.4	$	1,836

The aggregate intrinsic value in the preceding table represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $5.35 as of December 31, 2023, which would have been received by the option holders had all option holders exercised their options as of that date. The aggregate intrinsic value of options exercised was $0.6 million and $0.1 million for the years ended December 31, 2023 and 2022, respectively.

Employee Stock Purchase Plan (“ESPP”)

The Company has an employee stock purchase plan under which eligible employees may purchase a limited number of shares of common stock at a discount of up to 15% of the market value of such stock at pre-determined and plan-defined dates. There were 0.1 million and 0.2 million shares issued under the ESPP during the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, there were 0.3 million shares available for issuance under the ESPP.

Note 9 - Long-term Debt (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 22, 2020
Long-term Debt, Gross	$ 37,123
Debt Issuance Costs, Net, Total	$ 560	$ 840
The Credit Agreement [Member]
Debt Issuance Costs, Net, Total			$ 1,400
Line of Credit Facility, Interest Rate During Period	8.10%	5.00%
Line of Credit Facility, Interest Rate During Period	7.40%
Debt Instrument, Quarterly Payment, Thereafter	$ 1,000
Debt Instrument, Current Maturities, Excess Cash Flow Sweep	$ 2,100	$ 1,100
The Credit Agreement [Member] \| Secured Overnight Financing Rate (SOFR) [Member]
Debt Instrument, Interest Rate, State Floor Percentage	0.50%
The Credit Agreement [Member] \| Secured Overnight Financing Rate (SOFR) [Member] \| Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	3.25%
The Credit Agreement [Member] \| Base Rate [Member]
Debt Instrument, Interest Rate, State Floor Percentage	1.00%
The Credit Agreement [Member] \| The ABR Loan [Member] \| Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	1.50%
The Credit Agreement [Member] \| The ABR Loan [Member] \| Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	3.00%
The Credit Agreement [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Remaining Borrowing Capacity	$ 10,800
Term Loan [Member]
Long-term Debt, Gross	$ 30,723	$ 34,814
The SOFR Loan and Pricing Grid Credit Agreement [Member] \| The Credit Agreement [Member] \| Secured Overnight Financing Rate (SOFR) [Member] \| Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	2.00%
The Lenders [Member] \| The Credit Agreement [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity			25,000
The Lenders [Member] \| The Credit Agreement [Member] \| Letter of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity			10,000
The Lenders [Member] \| The Credit Agreement [Member] \| Swingline Loan Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity			10,000
The Lenders [Member] \| Term Loan [Member] \| The Credit Agreement [Member]
Long-term Debt, Gross			$ 40,000

Note 1 - Organization

12 Months Ended

Dec. 31, 2023

Business Description and Basis of Presentation [Text Block]

1.	Organization

Harvard Bioscience, Inc., a Delaware corporation (the “Company”), is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe and China, the Company sells through a combination of direct and distribution channels to customers around the world.

Note 13 - Revenues (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Contract with Customer, Liability, Revenue Recognized	$ 2.1	$ 2.5

Note 8 - Leases - Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating lease cost	$ 2,013	$ 1,971
Short-term lease cost	199	233
Sublease income	(102)	(102)
Total lease cost	$ 2,110	$ 2,102

Note 10 - Derivatives

12 Months Ended

Dec. 31, 2023

Derivatives and Fair Value [Text Block]

10.

Derivatives

On February 28, 2023, the Company entered into an interest rate swap contract to improve the predictability of cash flows from interest payments related to its variable, SOFR-based debt. The swap contract has a notional amount of $27.4 million as of December 31, 2023, and matures on December 22, 2025. This swap contract effectively converts the SOFR-based variable portion of the interest payable under the Credit Agreement into fixed-rate debt at an annual rate of 4.75%. The swap contract does not impact the additional interest related to the applicable interest rate margin as discussed above in Note 9, Long-Term Debt. The swap contract is considered an effective cash flow hedge, and as a result, net gains or losses are reported as a component of OCI in the consolidated financial statements and are reclassified as net income when the underlying hedged interest impacts earnings. An assessment is performed quarterly to evaluate the ongoing hedge effectiveness.

The following table presents the notional amount and fair value of the Company’s derivative instrument as of December 31, 2023:

(in thousands)		December 31, 2023
Derivatives Instruments	Balance Sheet Classification	Notional Amount		Fair Value (a)
Interest rate swap	Other long-term liabilities	$	27,375	$	(199	)

(a) See Note 11 for the fair value measurements related to this financial instrument.

The following table summarizes the effect of derivatives designated as cash flow hedging instruments for the year ended December 31, 2023:

	Year Ended
Derivatives Qualifying as Hedges, net of tax (in thousands)	December 31, 2023
Amount of loss recognized in OCI on derivatives (effective portion)	$	199
Amounts reclassified from accumulated other comprehensive loss to interest expense		120

Note 15 - Commitments and Contingent Liabilities

12 Months Ended

Dec. 31, 2023

Commitments and Contingencies Disclosure [Text Block]

15.

Commitments and Contingent Liabilities

In April 2022, the Company and HRGN executed a settlement with the plaintiffs in the HRGN Litigation (as defined below), which resolves all claims relating to the litigation as described in Note 16, Litigation Settlement.

The Company is involved in various other claims and legal proceedings arising in the ordinary course of business. After consultation with legal counsel, the Company has determined that the ultimate disposition of such proceedings is not likely to have a material adverse effect on its business, financial condition, results of operations or cash flow. Although unfavorable outcomes in the proceedings are possible, the Company has not accrued loss contingencies relating to any such matters as they are not considered to be probable and reasonably estimable. If one or more of these matters are resolved in a manner adverse to the Company, the impact on the Company’s business, financial condition, results of operations and cash flows could be material.

In addition, the Company has entered into indemnification agreements with its directors. It is not possible to determine the maximum potential liability amount under these indemnification agreements due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. The Company has not recorded any liability for costs related to contingent indemnification obligations as of December 31, 2023.

The Company is subject to unclaimed property laws in the ordinary course of its business. State escheat laws generally require entities to report and remit abandoned and unclaimed property to the state. Failure to timely report and remit the property can result in assessments that could include interest and penalties, in addition to the payment of the escheat liability itself. The Company is currently undergoing an unclaimed property audit. Based on the current stage of the audits, the Company has not accrued any significant losses related to these audits as of December 31, 2023.

Note 4 - Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Write-off of Fully Amortized Intangible Assets Related to Existing Technology and Discontinued Product Lines	$ 3,700
Capitalized Computer Software, Net	500
Amortization of Intangible Assets	$ 5,525	$ 6,122

Note 7 - Employee Benefit Plans - Fair Value and Asset Allocations of Pension Benefits (Details) - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Defined Benefit Plan, Actual Plan Asset Allocations

$ 16,940

$ 15,576

$ 27,252

100.00%

Debt Security, Corporate, US [Member]

Defined Benefit Plan, Actual Plan Asset Allocations

^[1]

$ 11,761

$ 11,714

69.00%

75.00%

Defined Benefit Plan, Equity Securities [Member]

Defined Benefit Plan, Actual Plan Asset Allocations

$ 3,567

$ 3,507

21.00%

23.00%

Defined Benefit Plan, Cash and Cash Equivalents [Member]

Defined Benefit Plan, Actual Plan Asset Allocations

$ 304

$ 185

2.00%

1.00%

Other Plan Assets [Member]

Defined Benefit Plan, Actual Plan Asset Allocations

$ 1,308

$ 170

8.00%

1.00%

[1]	Updated dimension from: "Debt Securities [Member]".

Note 7 - Employee Benefit Plans

12 Months Ended

Dec. 31, 2023

Retirement Benefits [Text Block]

7.	Employee Benefit Plans

Employee Retirement Savings Plans

The Company sponsors various qualified employee retirement savings plans and makes discretionary contributions to match a certain portion of employee contributions. The Company contributed $1.1 million to these plans for each of the years ended December 31, 2023 and 2022.

Employee Pension Plans

The Company’s subsidiary in the United Kingdom, Biochrom Ltd., maintains two defined benefit pension plans for its employees. In 2014, these defined benefit pension plans were closed to new employees, as well as closed to the future accrual of benefits for existing employees. The Company recognizes the funded status of the pension plans as an asset or liability in the consolidated balance sheets. The funded status equals the difference between the fair value of the plan’s assets and their benefit obligations and has historically measured each year as of December 31. The Company records net period benefit expense (credit) as a component of other expense in the Consolidated Statement of Operations.

The components of the Company’s net period benefit expense (credit) were as follows:

	Year Ended December 31,
(in thousands)	2023			2022
Interest cost	$	670		$	371
Expected return on plan assets		(788	)		(818	)
Net amortization loss		328			27
Net periodic benefit expense (credit)	$	210		$	(420	)

The following provides a reconciliation of the changes in the plans’ fair value of assets and benefit obligations for the years ended December 31, 2023 and 2022, and a summary of the funded status as of December 31, 2023 and 2022:

	December 31,
(in thousands)	2023			2022
Change in fair value of plan assets:
Balance at beginning of year	$	15,576		$	27,252
Actual return on plan assets		351			(9,098	)
Employer contributions		622			619
Benefits paid		(563	)		(592	)
Currency translation adjustment		954			(2,605	)
Balance at end of year	$	16,940		$	15,576

	December 31,
(in thousands)	2023			2022
Change in benefit obligation:
Balance at beginning of year	$	13,263		$	22,562
Interest cost		665			371
Actuarial loss (gain)		479			(6,912	)
Benefits paid		(563	)		(592	)
Currency translation adjustment		819			(2,166	)
Balance at end of year	$	14,663		$	13,263

	December 31,
(in thousands)	2023		2022
Fair value of plan assets	$	16,940	$	15,576
Benefit obligation		14,663		13,263
Net funded status	$	2,277	$	2,313

Changes in the actuarial loss (gain) disclosed above are primarily the result of changes in the discount rate and inflation assumptions due to underlying market conditions.

The amounts recognized in the consolidated balance sheets consist of:

	December 31,
(in thousands)	2023		2022
Other long-term assets	$	2,277	$	2,313
Accumulated other comprehensive loss		5,909		5,326

The weighted average assumptions used in determining the net pension cost for these plans follows:

	December 31,
(in thousands)	2023			2022
Discount rate		4.6	%		5.0	%
Expected return on assets		5.3	%		5.0	%

The discount rate assumptions used for pension accounting reflect the prevailing rates available on high-quality, fixed-income debt instruments with terms that match the average expected duration of the Company’s defined benefit pension plan obligations.

The Company’s mix of pension plan investments among asset classes also affects the long-term expected rate of return on plan assets. As of December 31, 2023, the Company’s actual asset mix approximated its target mix. Differences between actual and expected returns are recognized in the calculation of net periodic pension cost over the average remaining expected future working lifetime, which is approximately 7 years for active plan participants.

The asset allocations and fair value of the Company’s pension benefits as of December 31, 2023 and 2022, were as follows:

(in thousands)	2023				2022
Asset category:
Debt securities	$	11,761	69	%	$	11,714	75	%
Equity securities		3,567	21	%		3,507	23	%
Cash and cash equivalents		304	2	%		185	1	%
Other		1,308	8	%		170	1	%
Total	$	16,940	100	%	$	15,576	100	%

(in thousands)	2023		2022
Quoted Prices in Active Markets for Identical Assets (Level 1)	$	304	$	185
Significant Other Observable Inputs (Level 2)		16,636		15,391
Significant Other Unobservable Inputs (Level 3)		-		-
Total	$	16,940	$	15,576

Level 1 assets consist of cash and cash equivalents held in the pension plans. The Level 2 assets primarily consist of investments in private investment funds that are valued using the net asset values provided by the trust or fund, including an insurance contract. Although these funds are not traded in an active market with quoted prices, the investments underlying the net asset value are based on quoted prices.

The Company expects to contribute approximately $0.6 million to its pension plans during 2024. The benefits expected to be paid from the pension plans are $0.9 million in 2024, $0.7 million in 2025, $0.8 million in 2026, $1.0 million in 2027 and $0.8 million in 2028. The expected benefits to be paid in the five years from 2029 to 2033 are $5.0 million. The expected benefits are based on the same assumptions used to measure the Company’s benefit obligations at December 31, 2023.

The entire disclosure for retirement benefits.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480794/715-70-50-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480482/715-20-55-17

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//715/tableOfContent

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480266/715-60-50-3

Note 12 - Stock-Based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Share-based compensation	$ 5,000	$ 4,411
Continuing Operations [Member] \| Cost of Sales [Member]
Share-based compensation	308	121
Continuing Operations [Member] \| Selling and Marketing Expense [Member]
Share-based compensation	746	557
Continuing Operations [Member] \| General and Administrative Expense [Member]
Share-based compensation	3,560	3,487
Continuing Operations [Member] \| Research and Development Expense [Member]
Share-based compensation	$ 386	$ 246

Note 7 - Employee Benefit Plans - Defined Benefit Pension Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Interest cost	$ 665	$ 371
Expected return on plan assets	(788)	(818)
Net amortization loss	328	27
Net periodic benefit expense (credit)	$ 210	$ (420)

Note 9 - Long-term Debt - Breakdown of Borrowings (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Long-term debt, gross	$ 37,123
Less: unamortized deferred financing costs	(560)	$ (840)
Total debt	36,563	46,824
Less: current portion of long-term debt	(6,139)	(4,091)
Current unamortized deferred financing costs	280	280
Long-term debt	30,704	43,013
Term Loan [Member]
Long-term debt, gross	30,723	34,814
Line of Credit [Member]
Long-term debt, gross	$ 6,400	$ 12,850

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

Note 12 - Stock-Based Compensation - Activity of Restricted Stock and Restricted Stock Units (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Outstanding at December 31, 2021 (in shares)	1,238,776	1,404,816
Outstanding at December 31, 2021 (in dollars per share)	$ 3.15	$ 3.1
Outstanding at December 31, 2022 (in shares)	924,067	1,238,776
Outstanding at December 31, 2022 (in dollars per share)	$ 3.37	$ 3.15
Restricted Stock Units (RSUs) [Member]
Outstanding at December 31, 2021 (in shares)	1,093,801	1,141,164
Outstanding at December 31, 2021 (in dollars per share)	$ 3.94	$ 3.57
Options, Granted in Period (in shares)	1,350,125	918,870
Options, Granted in Period, Weighted Average Exercise Price (in dollars per share)	$ 2.87	$ 4.64
Restricted Stock Units, Vested in Period (in shares)	(1,144,065)	(733,611)
Restricted Stock Units, Vested, Grant Date Fair Value, Balance (in dollars per share)	$ 3.38	$ 4.08
Options, Cancelled / Forfeited in Period (in shares)	(134,865)	(232,622)
Options, Cancelled / Forfeited, Weighted Average Exercise Price (in dollars per share)	$ 3.71	$ 4.44
Outstanding at December 31, 2022 (in shares)	1,164,996	1,093,801
Outstanding at December 31, 2022 (in dollars per share)	$ 3.28	$ 3.94
Market Condition Restricted Stock Units [Member]
Restricted Stock Units Outstanding , Balance (in shares)	646,235	860,155
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share)	$ 4.51	$ 3.13
Restricted Stock Units, Granted in Period (in shares)	558,958	320,272
Restricted Stock Units Granted , Grant Date Fair Value, Balance (in dollars per share)	$ 2.61	$ 5.08
Restricted Stock Units, Vested in Period (in shares)	(316,210)	(401,308)
Restricted Stock Units, Vested, Grant Date Fair Value, Balance (in dollars per share)	$ 4.01	$ 2.11
Restricted Stock Units, Cancelled / Forfeited in Period (in shares)	(87,138)	(132,884)
Restricted Stock Units, Cancelled/ Forfeited , Grant Date Fair Value, Balance (in dollars per share)	$ 4.64	$ 4.21
Restricted Stock Units Outstanding , Balance (in shares)	801,845	646,235
Restricted Stock Units Outstanding , Grant Date Fair Value, Balance (in dollars per share)	$ 3.37	$ 4.51

Note 9 - Long-term Debt (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Debt [Table Text Block]

(in thousands)	December 31, 2023			December 31, 2022
Long-term debt:
Term loan	$	30,723		$	34,814
Revolving line		6,400			12,850
Less: unamortized deferred financing costs		(560	)		(840	)
Total debt		36,563			46,824
Less: current portion of long-term debt		(6,139	)		(4,091	)
Current unamortized deferred financing costs		280			280
Long-term debt	$	30,704		$	43,013

Schedule of Maturities of Long-Term Debt [Table Text Block]

(in thousands)
2024	$	6,139
2025		30,984
	$	37,123

Note 6 - Restructuring and Other Exit Costs - Restructuring and Other Exit Charges (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Balance	$ 636	$ 0
Restructuring and other exit costs	391	2,394
Non-cash charges	(142)	(1,471)
Cash payments	(801)	(287)
Balance	84	636
Cost of Revenues [Member]
Balance	0	0
Restructuring and other exit costs	320	1,471
Non-cash charges	(142)	(1,471)
Cash payments	(94)	0
Balance	84	0
Employee Severance [Member]
Balance	636	0
Restructuring and other exit costs	42	877
Non-cash charges	0	0
Cash payments	(678)	(241)
Balance	0	636
Other Restructuring [Member]
Balance	0	0
Restructuring and other exit costs	29	46
Non-cash charges	0	0
Cash payments	(29)	(46)
Balance	$ 0	$ 0

Note 14 - Income Tax

12 Months Ended

Dec. 31, 2023

Income Tax Disclosure [Text Block]

14.

Income Tax

Income tax expense for the years ended December 31, 2023 and 2022, consisted of:

	Year Ended December 31,
(in thousands)	2023		2022
Current income tax expense:
Federal and state	$	570	$	641
Foreign		61		194
		631		835
Deferred income tax expense (benefit):
Federal and state		132		(468	)
Foreign		96		(30	)
		228		(498	)
Total income tax expense	$	859	$	337

The effective tax rate for the year ended December 31, 2023 was (33.5)% as compared with (3.7)% for the same period in 2022. The difference between the Company’s effective tax rate year over year was primarily attributable to changes in the mix of pre-tax income and losses at individual subsidiaries, and the impact of changes in uncertain tax positions.

Income tax expense for the years ended December 31, 2023 and 2022, differed from the amount computed by applying the U.S. federal income tax rate of 21% to pre-tax loss as a result of the following:

	Year Ended December 31,
(in thousands)	2023			2022
Income tax benefit computed at federal statutory tax rate	$	(537	)	$	(1,927	)
Increase (decrease) in income taxes resulting from:
Permanent differences, net		(89	)		375
Non-deductible executive compensation		324			346
Global Intangible Low-Taxed Income (GILTI)		537			552
State income taxes, net of federal income tax benefit		(19	)		(295	)
Stock-based compensation		(329	)		69
Tax credits		(51	)		492
Net operating loss true-ups and expirations		1,140			431
Change in reserve for uncertain tax position		239			688
Impact of change to prior year tax accruals		(171	)		(232	)
Change in valuation allowance allocated to income tax		631			(102	)
Other		(816	)		(60	)
Total income tax expense	$	859		$	337

Income tax expense is based on the following pre-tax (loss) income from operations:

	Year Ended December 31,
(in thousands)	2023			2022
Domestic	$	(2,951	)	$	(9,099	)
Foreign		395			(80	)
Total	$	(2,556	)	$	(9,179	)

The tax effects of temporary differences that give rise to significant components of the deferred tax assets and deferred tax liabilities at December 31, 2023 and 2022, are as follows:

	Year Ended December 31,
(in thousands)	2023			2022
Deferred income tax assets:
Inventory	$	1,489		$	1,696
Operating loss and credit carryforwards		11,550			14,883
Research and development		3,908			2,000
Employee retention credit		1,435			-
Lease liabilities		1,317			1,538
Accrued expenses		818			621
Stock compensation		670			675
Deferred interest expense		386			881
Other assets		934			726
Total gross deferred assets		22,507			23,020
Less: valuation allowance		(15,222	)		(14,506	)
Deferred tax assets	$	7,285		$	8,514

Deferred income tax liabilities:
Indefinite-lived intangible assets	$	1,964		$	1,914
Definite-lived intangible assets		3,733			4,875
Lease right-of-use assets		959			1,148
Employee benefit plans		569			579
Other liabilities		400			255
Total deferred tax liabilities		7,625			8,771
Deferred income tax liabilities, net	$	(340	)	$	(257	)

Deferred income tax assets and liabilities by classification on the consolidated balance sheets were as follows:

	Year Ended December 31,
(in thousands)	2023			2022
Deferred tax assets (included in other long-term assets)	$	436		$	333
Deferred income tax liabilities		(776	)		(590	)
Deferred income tax liability, net	$	(340	)	$	(257	)

At December 31, 2023, the Company had state net operating loss carryforwards of $6.3 million, which expire between 2024 and 2043. The Company had net operating loss carryforwards of $7.8 million in certain foreign jurisdictions which may be carried forward indefinitely, partially offset by valuation allowances. The Company had $7.8 million of research and development tax credit carryforwards which begin to expire in 2024, and are partially offset by a reserve of $0.8 million for uncertain tax positions. The Company had a total of $2.7 million of state investment tax credit carryforwards, research and development tax credit carryforwards, and enterprise zone credit carryforwards, which begin to expire in 2024. In addition, the Company had a total of $0.4 million international R&D credits which begin to expire in 2037. The Internal Revenue Code (“IRC”) limits the amounts of net operating loss carryforwards or credits that a company may use in any one year in the event of a change in ownership under IRC Sections 382 or 383. As a result of various acquisitions in prior years, certain losses and credit carryforwards are subject to these limitations.

As of December 31, 2023 and 2022, the Company maintained a total valuation allowance of $15.2 million and $14.5 million, respectively, which relates to foreign, federal, and state deferred tax assets in both years. The valuation allowance is based on estimates of taxable income in each of the jurisdictions in which the Company operates and the period over which deferred tax assets will be recoverable. The net change in the total valuation allowance for the years ended December 31, 2023 and 2022, was an increase of $0.7 million and a decrease of $0.2 million, respectively. During the year ended December 31, 2023, the Company increased the valuation allowance related to the estimate of realizability of German deferred tax assets and deferred tax assets related to the Employee Retention Credit, offset by the utilization and expiration of certain U.S. federal and state net operating losses and the expiration of certain U.S. credits.

As of December 31, 2023 and 2022, cash and cash equivalents held by the Company’s foreign subsidiaries were $2.1 million and $2.6 million, respectively. As of December 31, 2023, the Company has determined the potential income tax and withholding liability related to available cash balances at foreign subsidiaries to be immaterial.

A summary of activity of unrecognized tax benefits is as follows:

	(in thousands)
Balance at December 31, 2021	$	1,332
Additions based on tax positions of prior years		534
Decreases based on tax positions of prior years		(34	)
Additions based on tax positions of current year		237
Other decreases, net		(86	)
Balance at December 31, 2022		1,983
Additions based on tax positions of prior years		13
Decreases based on tax positions of prior years		57
Additions based on tax positions of current year		245
Other decreases, net		(76	)
Balance at December 31, 2023	$	2,222

We expect the amount of unrecognized tax benefits to change within the next twelve months, including the release of reserves of approximately $0.4 million. Substantially all of the liability for uncertain tax benefits related to various federal, state and foreign income tax matters would benefit the Company's effective tax rate, if recognized. The Company classifies interest and penalties related to unrecognized tax benefits as a component of income tax expense, which has not been significant during the years ended December 31, 2023 and 2022, respectively.

With a few exceptions, the Company is no longer subject to income tax examinations by tax authorities in foreign jurisdictions for the years before 2019. In the U.S., the Company’s net operating loss and tax credit carryforward amounts remain subject to federal and state examination for tax years starting in 2004 as a result of tax losses incurred in prior years. There are currently no pending federal or state tax examinations.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

Note 14 - Income Tax - Pre-tax Income From Continuing Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Domestic	$ (2,951)	$ (9,099)
Foreign	395	(80)
Total	$ (2,556)	$ (9,179)

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-SubTopic 20
-Topic 940
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481913/940-20-25-1

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	80,000,000	80,000,000
Common stock, shares issued (in shares)	43,394,509	42,081,707
Common stock, shares outstanding (in shares)	43,394,509	42,081,707

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2023	Mar. 01, 2024	Jun. 30, 2023
Document Information [Line Items]
Entity Central Index Key	0001123494
Entity Registrant Name	HARVARD BIOSCIENCE INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-33957
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3306140
Entity Address, Address Line One	84 October Hill Road
Entity Address, City or Town	Holliston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01746
City Area Code	508
Local Phone Number	893-8999
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	HBIO
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 219,400,000
Entity Common Stock, Shares Outstanding		43,399,291
Auditor Firm ID	248
Auditor Name	GRANT THORNTON LLP
Auditor Location	Hartford, Connecticut

Note 11 - Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Fair Value as of December 31, 2023
Assets (Liabilities) (in thousands)	Level 1		Level 2			Level 3		Total
Equity securities - common stock	$	3,511	$	-		$	-	$	3,511
Interest rate swap agreements		-		(199	)		-		(199	)

Note 13 - Revenues - Deferred Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Deferred revenue	$ 4,508	$ 3,370	$ 4,266
Deferred Revenue, change	1,138	(896)
Service [Member]
Deferred revenue	2,849	1,530	1,976
Deferred Revenue, change	1,319	(446)
Customer Advances [Member]
Deferred revenue	1,659	1,840	$ 2,290
Deferred Revenue, change	$ (181)	$ (450)

Note 4 - Goodwill and Intangible Assets

12 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Text Block]

4.	Goodwill and Intangible Assets

The change in the carrying amount of goodwill is as follows:

	December 31,
(in thousands)	2023		2022
Carrying amount at beginning of period	$	56,260	$	57,689
Effect of change in currency translation		805		(1,429	)
Carrying amount at end of period	$	57,065	$	56,260

Intangible assets at December 31, 2023 and 2022 consist of the following:

			December 31, 2023							December 31, 2022
(in thousands)	Average				Accumulated							Accumulated
Amortizable intangible assets:	Life*		Gross		Amortization			Net		Gross		Amortization			Net
Distribution agreements/customer relationships		6	$	16,038	$	(9,706	)	$	6,332	$	16,124	$	(8,727	)	$	7,397
Existing technology & software development		2		35,007		(27,029	)		7,978		37,549		(26,482	)		11,067
Trade names and patents		3		7,613		(6,094	)		1,519		7,523		(5,197	)		2,326
Total amortizable intangible assets			$	58,658	$	(42,829	)	$	15,829	$	61,196	$	(40,406	)	$	20,790
Indefinite-lived intangible assets:									207							224
Total intangible assets								$	16,036						$	21,014

* Weighted average life in years as of December 31, 2023

During the year ended December 31, 2023, the Company wrote off approximately $3.7 million of fully amortized intangible assets of certain existing technology and other intangibles related to discontinued product lines. The Company capitalized $0.5 million of software development costs during the year ended December 31, 2023.

Intangible asset amortization expense was $5.5 million and $6.1 million for the years ended December 31, 2023 and 2022, respectively. Estimated amortization expense of existing amortizable intangible assets for each of the five succeeding years and thereafter is as follows:

(in thousands)
2024	$	5,281
2025		4,027
2026		2,366
2027		1,269
2028		1,546
Thereafter		1,340
Total	$	15,829

Note 5 - Balance Sheet Information - Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Compensation	$ 3,929	$ 3,476
Customer credits	3,201	2,368
Professional fees	499	392
Warranty costs	336	268
Other	1,240	982
Total	$ 9,205	$ 7,486

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

Marketable Securities, Policy [Policy Text Block]

Marketable Equity Securities

Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]

Allowance for Expected Credit Losses on Receivables

Inventory, Policy [Policy Text Block]

Inventories

Property, Plant and Equipment, Policy [Policy Text Block]

Property, Plant and Equipment

Property, plant and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets as follows:

Machinery and equipment (years)	3	-	10
Computer equipment and software (years)	3	-	7
Furniture and fixtures (years)	5	-	10

Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset.

Lessee, Leases [Policy Text Block]

Leases

Income Tax, Policy [Policy Text Block]

Income Taxes

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency

Earnings Per Share, Policy [Policy Text Block]

Earnings per Share

The following table sets forth the computation of basic and diluted earnings per share:

	Year Ended December 31,
(in thousands, except per share data)	2023			2022
Net loss	$	(3,415	)	$	(9,516	)
Weighted average shares outstanding - basic		42,420			41,413
Dilutive effect of equity awards		-			-
Weighted average shares outstanding - diluted		42,420			41,413
Basic loss per share	$	(0.08	)	$	(0.23	)
Diluted loss per share	$	(0.08	)	$	(0.23	)
Shares excluded from diluted loss per share due to their anti-dilutive effect		3,868			3,661

Comprehensive Income (Loss) [Policy Text Block]

Comprehensive Income (Loss)

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

Nature of contracts and customers

Performance obligations

Variable Consideration

Sales taxes, value added taxes, and certain excise taxes collected from customers and remitted to governmental authorities are accounted for on a net basis and are therefore excluded from revenues.

Contract Liabilities

Disaggregation of revenue

Refer to Note 13 for revenue disaggregated by type and by geographic location as well as further information about the deferred revenue balances.

Internal Use Software, Policy [Policy Text Block]

Software Development

Intangible Assets, Finite-Lived, Policy [Policy Text Block]

Intangible Assets

Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]

Goodwill

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-Lived Assets

Derivatives, Policy [Policy Text Block]

Derivatives

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Financial reporting standards define a fair value hierarchy that consists of three levels:

●

Level 1 includes instruments for which quoted prices in active markets for identical assets or liabilities accessible to the Company at the measurement date.

●

Level 3 includes valuations based on inputs that are unobservable and significant to the overall fair value measurement.

Share-Based Payment Arrangement [Policy Text Block]

Stock-based Compensation

Stockholders' Equity, Policy [Policy Text Block]

Preferred Stock

Segment Reporting, Policy [Policy Text Block]

Business Segment Information

Commitments and Contingencies, Policy [Policy Text Block]

Commitments and Contingencies

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

Accounting Pronouncements Adopted in 2023

Accounting Pronouncements yet to be Adopted

Reclassification, Comparability Adjustment [Policy Text Block]

Prior Period Financial Statement Reclassifications

Note 13 - Revenues - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues	$ 112,250	$ 113,335
Transferred at Point in Time [Member]
Revenues	108,558	111,927
Transferred over Time [Member]
Revenues	3,692	1,408
Instruments, Equipment, Software, and Accessories [Member]
Revenues	105,716	108,165
Service, Maintenance, and Warranty Contracts [Member]
Revenues	$ 6,534	$ 5,170

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares)	41,143,000
Balance	$ 452	$ 225,650	$ (132,674)	$ (10,027)	$ 83,401
Balance (in shares) at Dec. 31, 2021	41,143,000
Balance at Dec. 31, 2021	$ 452	225,650	(132,674)	(10,027)	$ 83,401
Stock option exercises (in shares)	40,000				40,267
Stock option exercises	$ 2	106	0	0	$ 108
Stock purchase plan (in shares)	176,000
Stock purchase plan	$ 0	469	0	0	469
Vesting of restricted stock units (in shares)	1,135,000
Vesting of restricted stock units	$ 0	0	0	0	0
Shares withheld for taxes (in shares)	(412,000)
Shares withheld for taxes	$ 0	(1,628)	0	0	(1,628)
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition	0	4,411	0	0	4,411
Net loss	0	0	(9,516)	0	(9,516)
Other comprehensive loss	$ 0	0	0	(5,025)	(5,025)
Balance (in shares)	42,082,000
Balance	$ 454	229,008	(142,190)	(15,052)	72,220
Balance (in shares) at Dec. 31, 2022	42,082,000
Balance at Dec. 31, 2022	$ 454	229,008	(142,190)	(15,052)	$ 72,220
Stock option exercises (in shares)	214,000				213,644
Stock option exercises	$ 0	506	0	0	$ 506
Stock purchase plan (in shares)	137,000
Stock purchase plan	$ 0	424	0	0	424
Vesting of restricted stock units (in shares)	1,460,000
Vesting of restricted stock units	$ 0	0	0	0	0
Shares withheld for taxes (in shares)	(498,000)
Shares withheld for taxes	$ 0	(2,523)	0	0	(2,523)
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition	0	5,000	0	0	5,000
Net loss	0	0	(3,415)	0	(3,415)
Other comprehensive loss	0	0	0	862	862
Other adjustments	$ (20)	20	0	0	0
Balance (in shares)	43,395,000
Balance	$ 434	$ 232,435	$ (145,605)	$ (14,190)	$ 73,074

Note 3 - Accumulated Other Comprehensive Loss

12 Months Ended

Dec. 31, 2023

Comprehensive Income (Loss) Note [Text Block]

3.	Accumulated Other Comprehensive Loss

Changes in the components of accumulated other comprehensive loss, net of tax, for the years ended December 31, 2023 and 2022, respectively, are as follows:

	Foreign Currency						Derivatives
	Translation			Defined Benefit			Qualifying
(in thousands)	Adjustments			Pension Plans			as Hedges			Total
Balance at December 31, 2021*	$	(8,778	)	$	(1,249	)	$	-		$	(10,027	)
Other comprehensive loss, net		(2,614	)		(2,411	)		-			(5,025	)
Balance at December 31, 2022*		(11,392	)		(3,660	)		-			(15,052	)
Other comprehensive income (loss), net		1,507			(446	)		(199	)		862
Balance at December 31, 2023	$	(9,885	)	$	(4,106	)	$	(199	)	$	(14,190	)

* See Note 2 – Prior Period Financial Statement Reclassifications

Note 18 - Government Assistance

12 Months Ended

Dec. 31, 2023

Government Assistance [Text Block]

18.

Government Assistance

As there is no authoritative guidance under U.S. GAAP on accounting for grants to for profit business entities from government entities, the Company accounts for government assistance by analogy to International Accounting Standards Topic 20, Accounting for Government Grants and Disclosure of Government Assistance (IAS 20). Under IAS 20, grants related to income are presented as part of the consolidated statements of operations either as a deduction of the related expense or reported separately in other income. The Company recognizes government assistance that supplements salaries or research activities as a reduction of the related operating expense over the period for which it is intended to compensate. Government assistance that is not directly related to expense reimbursement or relates to costs incurred in a previous fiscal period is recorded as other income.

For the years ended December 31, 2023 and 2022, the Company received $0.2 million and $0.7 million, respectively, under government assistance programs. The majority of the assistance was a result of the Company’s German subsidiaries participating in programs established to offset the negative impact of COVID-19 on profitability, to support employment during the COVID-19 pandemic, and to offset the costs of qualifying research and development activities.

In February 2024, the Company received and recorded $3.1 million for the Employee Retention Credit (“ERC”), which was enacted as part of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (“CARES Act”) to provide financial incentives to eligible businesses to retain their workforce through the period of financial hardship resulting from the COVID-19 pandemic.

Note 9 - Long Term Debt - Debt Maturity (Details) $ in Thousands	Dec. 31, 2023 USD ($)
2024	$ 6,139
2025	30,984
Total	$ 37,123

Note 7 - Employee Benefit Plans - Fair Value of Plan Assets By Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan, Fair Value of Plan Assets	$ 16,940	$ 15,576	$ 27,252
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan, Fair Value of Plan Assets	304	185
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan, Fair Value of Plan Assets	16,636	15,391
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan, Fair Value of Plan Assets	$ 0	$ 0

Note 4 - Goodwill and Intangible Assets - Change in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Carrying amount	$ 56,260	$ 57,689
Effect of change in currency translation	805	(1,429)
Carrying amount	$ 57,065	$ 56,260

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

Note 2 - Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Property, Plant and Equipment, Useful Lives [Table Text Block]

Machinery and equipment (years)	3	-	10
Computer equipment and software (years)	3	-	7
Furniture and fixtures (years)	5	-	10

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Year Ended December 31,
(in thousands, except per share data)	2023			2022
Net loss	$	(3,415	)	$	(9,516	)
Weighted average shares outstanding - basic		42,420			41,413
Dilutive effect of equity awards		-			-
Weighted average shares outstanding - diluted		42,420			41,413
Basic loss per share	$	(0.08	)	$	(0.23	)
Diluted loss per share	$	(0.08	)	$	(0.23	)
Shares excluded from diluted loss per share due to their anti-dilutive effect		3,868			3,661

Note 11 - Fair Value Measurements

12 Months Ended

Dec. 31, 2023

Fair Value Disclosures [Text Block]

11.

Fair Value Measurements

The following tables present the fair value hierarchy for those assets or liabilities measured at fair value on a recurring basis:

	Fair Value as of December 31, 2023
Assets (Liabilities) (in thousands)	Level 1		Level 2			Level 3		Total
Equity securities - common stock	$	3,511	$	-		$	-	$	3,511
Interest rate swap agreements		-		(199	)		-		(199	)

The Company uses the market approach technique to value its financial assets and liabilities. The Company’s financial assets and liabilities carried at fair value include, when applicable, investments in common stock and derivative instruments used to hedge the Company’s interest rate risks. The fair value of the Company’s investment in common stock of Harvard Apparatus Regenerative Technologies (“HRGN” formerly known as Biostage, Inc.) (see Note 16 for information regarding the HRGN Settlement) was based on the closing price as quoted on the OTCQB Marketplace at the reporting date. The fair value of the Company’s interest rate swap agreements was based on SOFR-yield curves at the reporting date.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Note 4 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

$ 58,658

$ 61,196

(42,829)

(40,406)

Indefinite-lived intangible assets:

15,829

20,790

207

224

Total intangible assets, Net

$ 16,036

21,014

Distribution Agreements/Customer Relationships [Member]

Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)

^[1]

6 years

$ 16,038

16,124

(9,706)

(8,727)

Existing Technology and Software Development [Member]

$ 6,332

7,397

Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)

2 years

$ 35,007

37,549

(27,029)

(26,482)

Trade Names and Patents [Member]

$ 7,978

11,067

Finite-Lived Intangible Assets, Weighted Average Useful Life (Year)

^[1]

3 years

$ 7,613

7,523

(6,094)

(5,197)

$ 1,519

$ 2,326

[1]	Weighted average life in years as of September 30, 2022

Note 5 - Balance Sheet Information (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Depreciation	$ 1,473	$ 1,453
Fully Depreciated and Disposed of Property and Equipment Removed From Fixed Asset Records	$ 2,000

Note 3 - Accumulated Other Comprehensive Loss (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

	Foreign Currency						Derivatives
	Translation			Defined Benefit			Qualifying
(in thousands)	Adjustments			Pension Plans			as Hedges			Total
Balance at December 31, 2021*	$	(8,778	)	$	(1,249	)	$	-		$	(10,027	)
Other comprehensive loss, net		(2,614	)		(2,411	)		-			(5,025	)
Balance at December 31, 2022*		(11,392	)		(3,660	)		-			(15,052	)
Other comprehensive income (loss), net		1,507			(446	)		(199	)		862
Balance at December 31, 2023	$	(9,885	)	$	(4,106	)	$	(199	)	$	(14,190	)

Note 14 - Income Tax (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

	Year Ended December 31,
(in thousands)	2023		2022
Current income tax expense:
Federal and state	$	570	$	641
Foreign		61		194
		631		835
Deferred income tax expense (benefit):
Federal and state		132		(468	)
Foreign		96		(30	)
		228		(498	)
Total income tax expense	$	859	$	337

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	Year Ended December 31,
(in thousands)	2023			2022
Income tax benefit computed at federal statutory tax rate	$	(537	)	$	(1,927	)
Increase (decrease) in income taxes resulting from:
Permanent differences, net		(89	)		375
Non-deductible executive compensation		324			346
Global Intangible Low-Taxed Income (GILTI)		537			552
State income taxes, net of federal income tax benefit		(19	)		(295	)
Stock-based compensation		(329	)		69
Tax credits		(51	)		492
Net operating loss true-ups and expirations		1,140			431
Change in reserve for uncertain tax position		239			688
Impact of change to prior year tax accruals		(171	)		(232	)
Change in valuation allowance allocated to income tax		631			(102	)
Other		(816	)		(60	)
Total income tax expense	$	859		$	337

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]

	Year Ended December 31,
(in thousands)	2023			2022
Domestic	$	(2,951	)	$	(9,099	)
Foreign		395			(80	)
Total	$	(2,556	)	$	(9,179	)

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	Year Ended December 31,
(in thousands)	2023			2022
Deferred income tax assets:
Inventory	$	1,489		$	1,696
Operating loss and credit carryforwards		11,550			14,883
Research and development		3,908			2,000
Employee retention credit		1,435			-
Lease liabilities		1,317			1,538
Accrued expenses		818			621
Stock compensation		670			675
Deferred interest expense		386			881
Other assets		934			726
Total gross deferred assets		22,507			23,020
Less: valuation allowance		(15,222	)		(14,506	)
Deferred tax assets	$	7,285		$	8,514

Deferred income tax liabilities:
Indefinite-lived intangible assets	$	1,964		$	1,914
Definite-lived intangible assets		3,733			4,875
Lease right-of-use assets		959			1,148
Employee benefit plans		569			579
Other liabilities		400			255
Total deferred tax liabilities		7,625			8,771
Deferred income tax liabilities, net	$	(340	)	$	(257	)

	Year Ended December 31,
(in thousands)	2023			2022
Deferred tax assets (included in other long-term assets)	$	436		$	333
Deferred income tax liabilities		(776	)		(590	)
Deferred income tax liability, net	$	(340	)	$	(257	)

Summary of Income Tax Contingencies [Table Text Block]

	(in thousands)
Balance at December 31, 2021	$	1,332
Additions based on tax positions of prior years		534
Decreases based on tax positions of prior years		(34	)
Additions based on tax positions of current year		237
Other decreases, net		(86	)
Balance at December 31, 2022		1,983
Additions based on tax positions of prior years		13
Decreases based on tax positions of prior years		57
Additions based on tax positions of current year		245
Other decreases, net		(76	)
Balance at December 31, 2023	$	2,222

Note 4 - Goodwill and Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Goodwill [Table Text Block]

	December 31,
(in thousands)	2023		2022
Carrying amount at beginning of period	$	56,260	$	57,689
Effect of change in currency translation		805		(1,429	)
Carrying amount at end of period	$	57,065	$	56,260

Schedule of Intangible Assets and Goodwill [Table Text Block]

			December 31, 2023							December 31, 2022
(in thousands)	Average				Accumulated							Accumulated
Amortizable intangible assets:	Life*		Gross		Amortization			Net		Gross		Amortization			Net
Distribution agreements/customer relationships		6	$	16,038	$	(9,706	)	$	6,332	$	16,124	$	(8,727	)	$	7,397
Existing technology & software development		2		35,007		(27,029	)		7,978		37,549		(26,482	)		11,067
Trade names and patents		3		7,613		(6,094	)		1,519		7,523		(5,197	)		2,326
Total amortizable intangible assets			$	58,658	$	(42,829	)	$	15,829	$	61,196	$	(40,406	)	$	20,790
Indefinite-lived intangible assets:									207							224
Total intangible assets								$	16,036						$	21,014

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

(in thousands)
2024	$	5,281
2025		4,027
2026		2,366
2027		1,269
2028		1,546
Thereafter		1,340
Total	$	15,829

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2

Note 4 - Goodwill and Intangible Assets - Future Amortization Expense of Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
2024	$ 5,281
2025	4,027
2026	2,366
2027	1,269
2028	1,546
Thereafter	1,340
Total	$ 15,829	$ 20,790

Note 13 - Revenues (Tables)

12 Months Ended

Dec. 31, 2023